Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Clinical Evaluation of Spherical Soft Contact Lenses, Toric Soft Contact Lenses and 
Spectacles in Low Astigmats
Protocol CR-6459
Version: 4.0
Date: 11 November 2021
Investigational Products: ACUVUE®Oasys 1 -Day contact lenses, ACUVUE®Oasys 1 -Day 
for Astigmatism contact lenses
Keywords: Sphere, Astigmatism, senofilcon A, ACUVUE®Oasys 1 -Day contact lenses, 
ACUVUE®Oasys 1 -Day for Astigmatism contact lenses, daily wear, daily disposable, 
dispensing, CLUE comfort, CLUE vision, CLUE handling, preference, logMAR visual 
acuity, Single use Eye -Cept®Rewetting Drops, LacriPure Saline Solution, ScleralFil 
Preservative Free Saline Solution.
Statement of Compliance to protocol, GC P and applicable regulatory guidelines:
This trial will be conducted in compliance with the proto col, ISO 14155 :2020 ,1the
International Council for Harmonization Good Clinical Practice E6 (R2) (ICH GCP) ,2the
Declaration of Helsinki ,3and all applicable regulatory requirements.
Confiden tiality Statement:
This document contains confidential information, which should not be copied, referred to, 
released or published without written approval from Johnson & Johnson Vision Care, Inc. 
The information may not be disclosed to others except to th e extent necessary to obtain 
Institutional Review Board/Independent Ethics  Committee approval and informed consent, or 
as required by International, Federal and State Laws, as applicable. Persons to whom this 
information is disclosed must be informed that this information is privi leged and confidential 
and that it should not be further disclose d without the written permission of Johnson & 
Johnson Vision Care, Inc. Any supplemental infor mation that may be added to this document 
is also confidential and propr ietary to Johnson & Johnson Vision Care, Inc. and must be kept 
in confidence in the same manner as the contents of this document.
CR-6459, v4.0
Page 1 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
TABLE OF CONTENTS 
PROTOCOL TITLE, NUMBER, VERSION AND DATE ................................ ...................... 7 
SPONSOR NAME AND ADDRESS ................................ ................................ ....................... 7 
MEDICAL MONITOR ................................ ................................ ................................ ............. 7 
AUTHORIZED SIGNATU RES ................................ ................................ ............................... 8 
CHANGE HISTORY ................................ ................................ ................................ ................ 9 
SYNOPSIS ................................ ................................ ................................ .............................. 10 
COMMONLY USED ABBREVIATIONS, ACRONYMS AND DEFINITIONS OF TERMS
................................ ................................ ................................ ................................ ................. 18 
1. INTRODUCTION AND BACKGROUND ................................ ................................ ...19 
1.1. Name and Descriptions of Investigational Products ................................ ................ 19 
1.2. Intended Use of Investigational Products ................................ ................................ .19 
1.3. Summary of Findings from Nonclinical Studies ................................ ...................... 19 
1.4. Summary of Known Risks and Benefits to Human Subjects ................................ ...19 
1.5. Relevant Literature References and Prior Cl inical Data Relevant to Proposed Clinical 
Study ……………………………………………………………………………………... 20 
2. STUDY OBJECTIVES, ENDPOINTS AND HYPOTHESES ................................ ......20 
2.1. Objectives ................................ ................................ ................................ ................. 20 
2.2. Endpoints ................................ ................................ ................................ .................. 20 
2.3. Hypotheses ................................ ................................ ................................ ............... 21 
3. TARGETED STUDY POPULATION ................................ ................................ ........... 22 
3.1. General Characteristics ................................ ................................ ............................ 22 
3.2. Inclusion Criteria ................................ ................................ ................................ ......22 
3.3. Exclu sion Criteria ................................ ................................ ................................ .....23 
3.4. Enrollment Strategy ................................ ................................ ................................ ..23 
4. STUDY DESIGN AND RATIONALE ................................ ................................ .......... 24 
4.1. Description of Study Design ................................ ................................ .................... 24 
4.2. Study Design Rationale ................................ ................................ ............................ 24 
4.3. Enrollment Target and Study Duration ................................ ................................ ....24 
5. TEST ARTICLE ALLOCATION AND MASKING ................................ ..................... 25 
5.1. Test Article Allocation ................................ ................................ ............................. 25 
5.2. Masking ................................ ................................ ................................ .................... 25 
5.3. Procedures for Maintaining and Breaking the Masking ................................ ........... 26 
6. STUDY INTERVENTION ................................ ................................ ............................. 26 
CR-6459, v4.0
Page 2 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
6.1. Identity of Test Articles ................................ ................................ ............................ 26 
6.2. Ancillary Supplies/Products ................................ ................................ ..................... 27 
6.3. Administration of Test Articles ................................ ................................ ................ 28 
6.4. Packaging and Labeling ................................ ................................ ........................... 28 
6.5. Storage Conditions ................................ ................................ ................................ ...29 
6.6. Colle ction and Storage of Samples ................................ ................................ .......... 29 
6.7. Accountability of Test Articles ................................ ................................ ................ 29 
7. STUDY EVALUATIONS ................................ ................................ .............................. 30 
7.1. Time and Event Schedule ................................ ................................ ......................... 30 
7.2. Detailed Study Procedures ................................ ................................ ....................... 32 
VISIT 1 ................................ ................................ ................................ ........................... 32 
VISIT 2 ................................ ................................ ................................ ........................... 35 
VISIT 3 ................................ ................................ ................................ ........................... 41 
VISIT 4 ................................ ................................ ................................ ........................... 44 
VISIT 5 ................................ ................................ ................................ ........................... 46 
FINAL EVALUATI ON................................ ................................ ................................ ..48 
7.3. Unscheduled Visits ................................ ................................ ................................ ...49 
7.4. Laboratory Procedures ................................ ................................ ............................. 50 
8. SUB JECTS COMPLETION/WITHDRAWAL ................................ .............................. 51 
8.1. Completion Criteria ................................ ................................ ................................ ..51 
8.2. Withdrawal/Discontinuation from the Study ................................ ........................... 51 
9. PRE-STUDY AND CONCOMITANT INTERVENTION/MEDICATION ................. 52 
9.1. Systemic Medications ................................ ................................ .............................. 52 
10. DEVIATIONS FROM THE PROTOCOL ................................ ................................ ..53 
11. STUDY TERMINATION ................................ ................................ ........................... 54 
12. PROCEDURE FOR HANDLING PRODUCT QUALITY COMPLAINTS .............. 55 
13. ADVERSE EVENTS ................................ ................................ ................................ ...56 
13.1.  Definitions and Classifications ................................ ................................ ............. 56 
13.2.  Assessing Adverse Events ................................ ................................ .................... 58 
13.2.1.  Causality Assessment ................................ ................................ .................... 59 
13.2.2. Severity Assessment ................................ ................................ ...................... 59 
13.3.  Documentation and Follow -Up of Adverse Events ................................ .............. 59 
13.4.  Reporting Adverse Events ................................ ................................ .................... 61 
13.4.1.  Reporting Adverse Events to Sponsor ................................ .......................... 61 
CR-6459, v4.0
Page 3 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
13.4.2.  Reporting Adverse Events to the Res ponsible IEC/IRB and Health Authorities
……………………………………………………………………………… 62 
13.5.  Event of Special Interest ................................ ................................ ....................... 62 
13.6.  Reporting of Pregnancy ................................ ................................ ........................ 62 
14. STATISTICAL METHODS ................................ ................................ ........................ 63 
14.1.  General Considerations ................................ ................................ ......................... 63 
14.2.  Sample Size Justification ................................ ................................ ...................... 63 
14.3.  Analysis Populations ................................ ................................ ............................ 65 
14.4.  Level of Statistical Significance ................................ ................................ ........... 65 
14.5.  Primary Analysis ................................ ................................ ................................ ..66 
14.6.  Secondary Analyses ................................ ................................ .............................. 67 
14.7.  Other Exploratory Analysis ................................ ................................ .................. 68 
14.8.  Interim Analysis ................................ ................................ ................................ ...68 
14.9.  Procedure for Handling Missing Data and Drop -Outs ................................ ......... 68 
14.10.  Procedure for Reporting Deviations from Statistical Plan ................................ ...68 
15. DATA HANDLING AND RECORD KEEPING/ARCHIVING ................................ 69 
15.1.  Electronic Case Report Form/Data Collection ................................ ..................... 69 
15.2.  Subject Record ................................ ................................ ................................ ......69 
15.3.  Trial Registration on ClinicalTrials.gov ................................ ............................... 70 
16. DATA MANAGEMENT ................................ ................................ ............................. 70 
16.1.  Access to Source Data/Document ................................ ................................ ........ 70 
16.2.  Confidentiality of Information ................................ ................................ .............. 70 
16.3.  Data Quality Assurance ................................ ................................ ........................ 70 
16.4.  Data Monitoring Committee (DMC) ................................ ................................ ....71 
17. CLINICAL MONITORING ................................ ................................ ........................ 71 
18. ETHICA L AND REGULATORY ASPECTS ................................ ............................ 71 
18.1.  Study -Specific Design Considerations ................................ ................................ .71 
18.2.  Investigator Responsibility ................................ ................................ ................... 71 
18.3.  Independent Ethics Committee or Institutional Review Board (IEC/IRB) .......... 72 
18.4.  Informed Consent ................................ ................................ ................................ .73 
18.5.  Privacy of Personal Data ................................ ................................ ...................... 73 
19. STUDY RECORD RETENTION ................................ ................................ ................ 74 
20. FINANCIAL CONSIDERATIONS ................................ ................................ ............ 75 
21. PUBLICATION ................................ ................................ ................................ ........... 75 
CR-6459, v4.0
Page 4 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
22. REFERENCES ................................ ................................ ................................ ............ 75 
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES) .....77 
APPENDIX B: PATIENT INSTRUCTION GUIDE ................................ ........................... 109 
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT) ................................ ....... 110 
APPENDIX D: ................................ ....139 
 LENS FITTING CHARACTERISTICS ................................ ............................ 140 
 SUBJECT REPORTED OCULAR OUTCOMES ................................ ............. 146 
 DETERMINATION OF DISTANCE SPHEROCYLINDRICAL REFRACTIONS
................................ ................................ ................................ ................................ ............... 148 
 BIOMICROSCOPY SCALE ................................ ................................ ............. 154 
 DISTANCE AND NEAR VISUAL ACUITY EVALUATION ........................ 160 
 TORIC FIT EVALUATION ................................ ................................ .............. 165 
 ETDRS DISTANCE VISUAL ACUITY MEASUREMENT PROCEDURE ..170 
 PATIENT REPORTED OUTCOMES ................................ .............................. 174 
 LENS INSERTION AND REMOVAL ................................ ............................. 176 
 VISUAL ACUITY CHART LUMINANCE AND ROOM ILLUMINATION 
TESTING ................................ ................................ ................................ .............................. 179 
APPENDIX E: GUIDELINES FOR COVID -19 RISK MITIGATION ............................... 188 
PROTOCOL COMPLIANCE INVESTIGATOR(S) SIGNATURE PAGE ........................ 200 
 
LIST OF TABLES
Table 1: Test and Control Article Parameters ................................ ................................ ......... 27 
Table 2: Ancillary Supplies ................................ ................................ ................................ ....27 
Table 3: Time and Events ................................ ................................ ................................ ....... 30 
Table 4: Disallowed systemic medications ................................ ................................ ............. 52 
Table 5: Disallowed systemic antihistamines ................................ ................................ ......... 53 
Table 6: Examples of major and minor protocol deviations ................................ ................... 54 
Table 7: Historical Data from ................................ ................................ .................. 63 
Table 8: Power Calculation for the Visual Performanc e (HLHC logMAR) for the primary 
hypothesis with Type I error of 0.05. ................................ ................................ ...................... 64 
Table 9: Power of the First Secondary Hypothesis of CLUE Vision score for the first secondary 
hypothesis (S1) with Type I error of 0.05. ................................ ................................ .............. 64 
Table 10: Power of the Visual Performance (HLHC lo gMAR) for the second secondary 
hypothesis (S2). ................................ ................................ ................................ ....................... 64 
Table 11: Power Calculation for the Contact Lens Preference (superiority) for the third 
secondary hypothesis (S3). ................................ ................................ ................................ .....64 
CR-6459, v4.0
Page 5 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
 
LIST OF FIGURES
Figure 1: Study Flowchart ................................ ................................ ................................ ......17 
Figure 2: Gatekeeping strategy and α-propagation, P1 –Primary hypothesis and S1 -3–the 
first to third secondary hypothesis defin ed in section 2.3. ................................ ...................... 66 
 
CR-6459, v4.0
Page 6 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
PROTOCOL TITLE, NUMBER, VERSION  AND DATE  
Title: Clinical Evaluation of Spherical Soft Contact Lenses, Toric Soft Contact Lenses and 
Spectacles in Low Astigmats
Protocol Number: CR-6459
Version: 4.0
Date: 11November 2021
SPONSOR NAME AND ADDRES S 
Johnson & Johnson Vision Care , Inc. (JJVC)
7500 Centurion Parkway 
Jacksonville, FL 32256
MEDICAL MONITOR  
The Medical Monitor must be notified by t he clinical institution/site by e -mail or telephone 
within 24 hours of learning of a Serious Adverse Event. The Medical Monitor may be 
contacted during business hours for adverse event questions. General study related questions 
should be directed towards y our assigned clinical research associate.
The Medical Monitoring Plan is mainta ined as a separate document and inc luded in the Trial 
Master File.
 
CR-6459, v4.0
Page 7 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
AUTHORIZED SIGNATURES  
The signature sbelow constitutes the approval of this  protocol and the attachments and 
provide the necessary assurances that this tria l will be conducted according to all stipulations 
of the protocol, including all statements regarding confidentiality, and according to local 
legal and regulatory requirements and applicable U.S. federal regulations,4ISO 14155 :2020 ,1
ICH guidelines,2and the Declaration of Helsinki.3
Author & Study 
Responsible Clinician
See Electronic Signature Report 
DATE
Clinical Operations 
Manager See Electronic Signature Report
DATE
Biostatistician See Electronic Signature Report
DATE
Biostatistician
Reviewer See Electronic Signature Report
DATE
Data Management See Electronic Signature Report
DATE
Medical Safety 
Officer See Electronic Signature Report
DATE
Approver See Electronic Signature Report
DATE
CR-6459, v4.0
Page 8 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
SYNOPSIS 
Protocol Title Clinical Evaluation of Spherical Soft Contact Lenses, Toric 
Soft Contact Lenses and Spectacles in Low Astigmats
Sponsor JJVC, 7500 Centurion Parkway, Jacksonville, FL  32256
Clinical Phase Clinical trial phase: Post-market
Design control phase: Post-market, phase 4
Trial Registration This study will be registered on ClinicalTrials.gov by the 
Sponsor.
Test Article(s) Approved Products: ACUVUE®Oasys 1-Day contact lenses
(AO1D) , ACUVUE®Oasys 1-Day for Astigmatism 
(AO1DfA) contact lenses.
Wear and Replacement 
SchedulesWear Schedule: Daily wear
Replacement Schedule: Daily disposable
Objectives Primary Objective
The primary objective of this study is to evaluate the
difference in High-Luminance, High-Contrast (HLHC) 
Visual Acuity (VA) between binocular correction with 
AO1DfA and AO1D contact lenses in habitual contact lens 
wearers with low astigmatism.
Secondary Objectives
The secondary objectives of th is study are to assess the 
CLUE subjective vision score and subject overall preference for AO1DfA and AO1D contact lenses in habitual contact 
lens wearers with low astigmatism. HLHC VA will also be 
assessed with subjects wearing their own habitual spectacle 
correction and compared to that with the AO1DfA lens.
CR-6459, v4.0
Page 10 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Study Endpoints Primary endpoint:
xHLHC VA at 1-week follow- up for contact lens wear
periods
Secondary endpoints:
xCLUE vision score at 1-week follow- up for contact
lens wear periods
xSubjective preference between sphere and toric
correction at the final study visit
xHLHC VA with spectacle wear at the end of the
washout period
Other observations (efficacy):
xHigh-Luminance, Low- Contrast (HLLC) VA at 1-
week follow-up , and with spectacle wear at the end of
the washout period
xNumber of diagnostic lenses required to achieve fit
success for the contact lens corrections
xLength of time required to fit the contact lens
corrections
xCLUE comfort and handling scores at 1- week follow-
up for the contact lens corrections and CLUE vision
with spectacle wear at the end of the washout period
xMRD and National Eye Institute Refractive Error
Quality of Life Instrument (NEI-RQL) qu estionnaire
response for the contact lens corrections and with
spectacle wear at the end of the washout period
xSubjective ranking of corrections (sphere, toric, and
habitual spectacles) in orde r of preference at the final
visit
xAverage wear time and comfortable wear time for the
contact lens corrections
xLens fitting characteristics for the contact lens
corrections
xSettled lens orientation (for the AO1DfA contact
lenses only)
xSubject reported ocular symptoms
Other observations (safety):
xSlit lamp findings
xAdverse events
Primary Hypothesis: 
1.After 1 week of wear, monocular HLHC VA for
correction with AO1DfA lenses will be superior to that
for mean sphere correction with AO1D spherical
lenses.
CR-6459, v4.0
Page 11 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Secondary Hypotheses:
1.After 1 week of wear , the mean CLUE vision score for
binocular correction with AO1DfA lenses will be
superior to that for binocular mean sphere correction
with AO1D spherical lenses.
2.After 1 week of wear, subjects will have greater
overall preference for binocular correction with
AO1DfA lenses over AO1D spherical lenses.
3.After 1 week of wear HLHC VA for correction with
AO1DfA lenses will be non-inferior to that for
correction with subjects’ habitual spectacles , using a
non-inferiority boundary of -0.05 logMAR.
Study Design This will be a 5-visit, ra ndomized, partially single-masked, 
bilateral wear, dispensing, 2 -treatment × 2- period crossover 
study with spectacle-wear washout and wash-in periods.
Subjects will be randomized into one of two unique 
sequences to wear each contact lens correction one at a time 
(sphere followed by toric or toric followed by sphere sphere).
For each of the two wear periods, lenses will be worn bilaterally in a daily wear, daily disposable modality for 7(±2) days
. There will be a 7(±2) day wash-in period prior to 
the first study lens wear period, and a 7(±2) day washout 
period between the first and second wear periods. During the
wash -in and washout periods, subjects will only wear their 
own habitual spectacle correction (i.e., no contact lens wear).
Subjective comfort, vision and handling will be assessed at 
fitting and follow -up visits for each contact lens wear period 
using the CLUE questionnaire, and CLUE vision will also be 
assessed at the end of the washout period. HLHC VA and 
HLLC VA will be assessed with the study contact lenses at the 1
-week follow-up visits and with spectacle wear at the
end of the washout period. At the final study visit, contact 
lens preference will be assessed (i.e., preference between the study contact lenses) as well as overall correction 
ranking
(i.e., corrections ranked by preference considering both study 
lense s and habitual spectacles). 
See the flow chart at the end of the synopsis table for the 
schematic of the study visits and procedures of main observations (Figure 1).
Sample Size This study will have an enrollment target of approximately 
170subjects, with a target of at least 153 to complete
(assuming a dropout rate of approximately 10%).
Study Duration Total study duration including the enrollment period is 
anticipated to be approximately 11 weeks.
CR-6459, v4.0
Page 12 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Anticipated Study 
PopulationSubjects will be habitual soft contact lens wearers with
bilateral astigmatism who are between 18 and 39 years of 
age (inclusive).
CR-6459, v4.0
Page 13 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Eligibility Criteria -
InclusionPotential subjects must satisfy of all the following criteria to 
be enrolled in the study.
Inclusion Criteria following Screening
The subject must:
1.Read, understand, and sign the STATEMENT OF
INFORMED CONSENT and receive a fully executedcopy of the form.
2.Appear able and willin g to adhere to the instructions set
forth in this clinical protocol.
3.Be between 18 and 39 (inclusive) years of age at the time
of screening.
4.By self-report, habitually wear soft contact lenses (sphere
or toric) in both eyes in a daily reusable or daily
disposable wear modality (i.e. not extended wear
modality). Habitual wear is defined as a minimum of 6
hours of wear per day, for a minimum of 2 days per week
during the 4 weeks.
5.Possess a wearable pair of spectacles that provide
correction for distance vision.
Inclusion Criteria at Baseline Evaluation
The subject must:
6.In both eyes, have magnitude of the cylinder component
of their vertex-corrected distance refraction greater than
or equal to 0.625 DC and less than 1.625 DC.
7.In both eyes, have the mean sphere of their vertex-
corrected distance refraction minus half of the indicated
contact lens label cylinder power be between - 0.875 to -
4.625 DS (inclusive).
8.For each eye, have the cylinder axis of their distance
refraction between 165° and 15° (i.e., 180±15°, inclusive)
or between 75° and 105° (i.e., 90±15°, inclusive).
9.For both eyes, have the sphere power of the ir habitual
spectacles within ±0.50 Diopters Sphere (DS) (inc lusive)
of the sphere power of their current subjective refraction.
10.For both eyes, have the cylinder power of their habitual
spectacles within ±0.50 Diopters Cylinder (DC)
(inclusive) of the cylinder power of their currentsubjective refraction.
11.For both eyes, have the cylinder axis of their habitual
spectacles within ±20° (inclusive) of the cylinder axis of
their current subjective refraction.
12.Achieve monocular VA of 20/30 or better with their
habitual spectacles in both eyes.
CR-6459, v4.0
Page 14 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Eligibility Criteria –
ExclusionPotential subjects who meet any of the following criteria will 
be excluded from participating in the study: 
Exclusion Criteria following Screening
The subject must not:
1.Be currently pregnant or lactating.
2.Be diabetic.
3.Be currently using any ocular medications or have any
ocular infection of any type.
4.By self-report, have any ocular or systemic disease,
allergies, infection, or use of medication that mightcontraindicate or interfere with contact lens wear, or
otherwise compromise study endpoints, including
infectious disease (e.g., hepatitis, tuberculosis),contagious immunosuppressive disease (e.g., HumanImmunodeficiency Virus [
HIV]), autoimmune disease
(e.g. rheumatoid arthritis, Sjögren’s syndrome), or history
of serious mental illness or seizures. See section 9.1 for
additional details regarding excluded systemic
medications.
5. Have habitually worn rigid gas permeable (RGP) lenses,
orthokeratology lenses, or hybrid lenses (e.g.
SynergEyes, SoftPerm) within the past 6 months.
6.Be currently wearing monovision or multi focal contact
lenses.
7.Be currently wearing lenses in an extended wear
modality.
8.Have a history of strabismus or amblyopia.
9.Be an employee (e.g., Investigator, Coordinator,
Technician) or immediate fa mily member of an employee
(including partner, child, par ent, grandparent, grandchild
or sibling of the employee or their spouse) of the clinical
site.
10. Have participated in a contact lens or lens care product
clinical trial within 7 days prior to study enrollment.
Exclusion Criteria at Baseline Evaluation
The s ubject must not:
11.Have clinically significant (g rade 3 or higher on the FDA
grading scale) slit lamp findings (e.g., corneal edema,
neovascularization or stai ning, tarsal abnormalities or
bulbar injection) or other corneal or ocular disease or
abnormalities that contraindicate contact lens wear or
may otherwise compromise study endpoints (including
entropion, ectropion, chalazia, recurrent styes, glaucoma,
CR-6459, v4.0
Page 15 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
history of recurrent corneal erosions, aphakia, moderate 
or above corneal distortion, herpetic keratitis).
12. Have fluctuations in vision due to clinically significant
dry eye or other ocular conditions.
13.Have had or have planned (within the study period) any
ocular or intraocular surgery (e.g., radial keratotomy,
PRK, LASIK, iridotomy, retinal laser photocoa gulation,
etc.).
Disallowed Medications/Interventions Subjects will not be eligible to enroll if they are taking any ocular medications, or any systemic medications that would normally contraindicate contact lens wear 
or may otherwise 
compromise study endpoints . See section 9.1 for details 
regarding disallowed systemic medications.
Measurements and Procedures The key procedure associated with the endpoints for this study will be
:
- Fitting of toric and spherical contact l enses, including 
timing of the fitting process
- Evaluation of subjective vision, comfort, handling and 
lens preference using PRO questionnaires
-Measurement of HLHC and HLLC VA using ETDRS charts
Microbiology or Other Laboratory Testing Not applicable for this study.
Study Termination The occurrence of an Unanticipated Adverse Device Effect (UADE) or 
Serious Adverse Event (SAE) for which a causal 
relationship to a test article cannot be ruled out, will result in 
stopping further dispensing investigational product. In the event of a UADE or SAE, the Sponsor Medical Monitor may unmask the treatment regimen of subject(s) and may discuss this with the Principal Investigator before any further 
subjects are enrolled.
Ancillary Supplies/ Study-Specific Materials Lens cases, fluorescein strips and preservative-free rewetting 
drops / artificial tears will be supplied for use as needed.  
Principal Investigator(s) and Study Institution(s)/Site(s) A full list of Principal Investigators, clinical sites, and institutions is kept separately from the Study Protocol and is included in the study Trial Master File.
CR-6459, v4.0
Page 16 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Figure 1: Study Flowchart
Visit 1: Screening
Habitual contact lenses must be worn to this visit
Statement of Informed Consent
Demographics
Medical History & Concomitant Medications
Habitual Contact Lens Information
Eligibility at Screening
Baseline Evaluation
Baseline PRO questionnaire (habitual lenses)
Entrance visual acuity
Spherocylindrical refraction and distance visual acuity
Measurement of habitual spectacles power
Slit lamp biomicroscopy
Eligibility after Baseline
Continuance & Lens Fitting (#1 through #2)
Review med history and medicationsSubject reported ocular symptoms
Entrance VA and biomicroscopyLens assignment and insertion
Lens
fit assessment, including rotation for toric lenses
Spherical over-refraction, modification if required
PRO post-fit questionnaire
Lenses dispensed for 7 r2 days
Follow-up (#1 through #2)
Study lenses must be worn for ≥ 1 hour prior to visit
PRO follow-up questionnaire
ETDRS HLHC and HLLC visual acuity
Lens fit assessment, including rotation for toric lenses
Lens removal
Biomicroscopy
Schedule next visitSpectacle Evaluation
PRO follow -up questionnaire
ETDRS HLHC and HLLC visual acuity
Final Evaluation
Spherocylindrical refractionCompletion status
Biomicroscopy (if discontinued early)After follow-up #1
After follow-up #2Washout Period
A washout period of 7r2 days during 
which subjects will only wear their 
habitual spectaclesWash-in Period
A wash -in period of 7 r2 days during 
which subjects will only wear their 
habitual spectacles
CR-6459, v4.0
Page 17 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
COMMONLY USED ABBREVIATIONS , ACRONYMS  AND DEFINITIONS OF 
TERMS  
ADE Adverse Device Effect
ADHD Attention Deficit Hyperactivity Disorder
AE Adverse Event/Adverse Experience
AO1D ACUVUE OASYS®1-DAY with HydraLuxe™ TECHNOLOGY
AO1DfA ACUVUE OASYS®1-DAY with HydraLuxe™ TECHNOLOGY for 
ASTIGMATISM
BSCVA Best Spectacle Corrected Visual Acuity
CFR Code of Federal Regulations
CLUE Contact Lens User Experience
COM Clinical Operations Manager
CRA Clinical Research Associate
CRF Case Report Form
CRO Contract Research Organization
D Diopter
DMC Data Monitoring Committee
eCRF Electronic Case Report Form
EDC Electronic Data Capture
ESD Eyelid Stabilized Design
ETDRS Early Treatment Diabetic Retinopathy Study
FDA Food and Drug Administration
GCP Good Clinical Practice
HIPAA Health Insurance Portability and Accountability Act
HIV Human Immunodeficiency Virus
IB Investigator’s Brochure
ICH The International Council for Harmonization
IEC Independent Ethics Committee
IRB Institutional Review Board
ISO International Organization for Standardization
ITT Intent -to-Treat
JJVC Johnson & Johnson Vision Care, Inc.
LASIK Laser -Assiste d in Situ Keratomileusis
LogMAR Logarithm of Minimal Angle of Resolution
NEI-RQL National Eye Institute Refractive Error Quality of Life Instrument
OD Right Eye
OS Left Eye
OU Both Eyes
PIG Patient Instruction Guide
PQC Product Quality Complai nt
PRK Photorefractive Keratectomy
PRO Patient Reported Outcome
QA Quality Assurance
SAE Serious Adverse Event/Serious Adverse Experience
CR-6459, v4.0
Page 18 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
SAS Statistical Analysis System
SD Standard Deviation
UADE Unanticipated Adverse Device Effect
USADE Unanticipated Serious Adverse Device Effect
VA Visual Acuity
1.INTRODUCTION AND BACKGROUND
Market research data suggests that , particularly in some international markets, patients with 
low astigmatism are often prescribed spherical contact lenses rather than toric lenses.5A
previous study conducted by JJVC using hydrogel lenses ( ) demonstrated that toric 
lenses provide superior h igh and low contrast visual acuity andbetter visual comfort 
compared to spherical lenses in a population of low astigmats.4This study aims to expan d on 
the results of the previous research by evaluating CLUE vision scores with sphere and toric 
correction with silicone hydrogel lenses , and also comparing the corrected visual acuity to 
that with subjects’ habitual spectacles. To ensure a valid comparis on, subjects’ habitual 
spectacles must be within ±0.50 DS for the sphere component, ±0.50 DC for the cylinder 
component, and ±20 degrees for the axis of their current subjective refraction in both eyes, 
consistent with the 95% limits of agreement for repea tability of these refractive component s.6
1.1. Name and Descriptions of Investigational Products 
Two currently marketed contac t lenses will be evaluated in this study; ACUVUE®Oasys 1 -
Day (AO1D )spherical lenses and ACUVUE®Oasys 1 -Day fo r Astigmatism (AO1DfA) toric 
lenses. Further details about the test articles are found in section 6of this protocol.
1.2. Intended Use of Investigational Products  
The int ended use of the study lenses is the corr ection of myopia and associated astigmatism 
in the case of the AO1DfA lens. Study lenses will  be worn bilaterally in a daily wear, daily 
disposable modality for at least 8hours per day and 5 days per week over a we ar period of 
7±2 days. Two wear periods will be completed in total, with a washout period of 7(±2) days
between the wear periods and a wash -in period of 7(±2) days prior to the first wear period. 
1.3. Summary of Findings from Nonclinical Studies  
Not Applicable –marketed product only.
1.4. Summary of Known Risks and Benefits to Human Subjects  
The anticipated clinical benefit of the study lense s will be the correction of refractive error. 
No adverse device effects are anticipated. The risks associated w ith use of the study lenses 
are considered to be the same as those for other marketed soft contact lenses worn in the 
same modality (i.e., daily disposable wear), a nd these risks are considered acceptable relative 
to the clinical benefits. C omprehensive risk and benefit information regarding the study 
lenses is included in theAO1D and AO1DfA package inserts ( Appendix C).
CR-6459, v4.0
Page 19 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
1.5. Relevant Literature References and Prior Clinical Data Relevant to Prop osed 
Clinical Study  
The AO1D and AO1DfA lenses are FDA -approved and have been marketed commercially 
since 2016 and 2017, respectively .For further details regarding prior clinical data, refer to 
theAO1D and AO1DfA package inserts (Appendix C).
2.STUDY OBJECTIVES, ENDPOINTS AND HYPOTHESES
2.1. Objectives 
Primary Objective
The primary objective of this study istoevaluate the difference in High -Luminance, High -
Contrast (HLHC) Visual Acuity (VA) between binocular correction with AO1DfA and 
AO1D contact lenses in habitual contact lens wearers with low astigmatism.
Secondary Objectives
The secondary objectives of th is study are to assess the CLUE subjective vision score and 
subject overall prefere nce for AO1DfA and AO1D contact lenses in habitual contact lens 
wearers with low astigmatism. HLHC VA will al so be assessed with subjects wearing their 
own habitual spectacle correction and compared to that with the AO1DfA lens .
2.2. Endpoints  
Primary endpoint
The primary endpoint will be the HLHC VA for the contact lens wear periods .
HLHC VA will be assessed using ETDRS charts under controlled lighting conditions, which 
will be monitored and verified each tes ting day (room illumination greater than 4 00 lux, and 
chart luminance between 120 and 200 cd/m2). VA will be scored letter -by-letter in logMAR 
units. 
Secondary Endpoints
Secondary endpoints for this study will be the subject overall preference between sphere 
(AO1D) and toric (AO1DfA) correction at the final study visit, the CLUE vision score at 1 -
week follow -upfor each contact lens correction (AO1D, AO1DfA) at follow -up, and the 
HLHC VA with spectacle correction .
Subjective quality of vision will be  assessed using Contact Lens User Experience (CLUE) 
questionnaire. CLUE is a patient -reported outcomes questionnaire to assess patient -
experience attributes of soft, disposable contact lenses (comfort, vision, handling, and 
packaging) in a contact -lens wearing population in the US, ages 18 -65. Derived CLUE scores 
using Item Response Theory (IRT) follow a normal distribution with a population average 
score of 60 (SD 20), where higher scores indicate a more favorable/positive response.8A 5-
point increase in an average CLUE score translates into 10% shift in the distribution of 
scores for population of soft disposable contact lens wearers.
CR-6459, v4.0
Page 20 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Overall preference between AO1D and AO1DfA correct ion will be assessed using a 
preference questionnaire at the final visit. The questionnaire will include ‘no overall 
preference’ option. 
Other Exploratory Endpoints
Exploratory endpoints for this study will be:
Other observations (efficacy) :
xHigh -Luminan ce, Low -Contrast (HLLC) VA at follow -up,andwith spectacle wear at
the end of the washout period
xNumber of diagnostic lenses required to achieve fit success for the contact lens
corrections
xLength of time required to fit the contact lens corrections
xCLUE comfort and handling scores at 1 -week follow -up for the contact lens
corrections , and CLUE vision with spectacle wear at the end of the washout period
xMRD and NEI -RQL questionnaire response for the contact lens corrections and with
spectacle wear at the e nd of the washout period
xSubjective ranking of corrections (sphere, t oric, and habitual spectacles) in order of
preference at the final visit
xAverage wear time and comfortable wear  time for the contact lens corrections
xLens fitting characteristics for the contact lens corrections
xSettled lens orientation (for the AO1DfA contact lenses only)
xSubject reported ocular symptoms
Other observations (safety):
xSlit lamp findings
xAdverse events
2.3. Hypotheses  
Primary Hypothesis
1.After 1 week of wear, monocu lar HLHC VA for correcti on with AO1DfA lenses will
be superior to that for mean sphere correction with AO1D spherical lenses.
Secondary Hypotheses
1.After 1 week of wear, the mean CLUE vi sion score for binocular correction with
AO1DfA lenses will be superior to that for binocular mean sphere correction with
AO1D spherical lenses.
2.After 1 week of wear HLHC VA for correction with AO1DfA lenses will be non -
inferior to thatfor correction with subjects’ habitual spectacles, using a n on-inferiority
boundary of -0.05 logMAR.
3.After 1 week of wear, subjects will have  greater overall preference for binocular
correction with AO1DfA lenses over AO1D spherical lenses.
The primary hypothesis must be met for the study to be considered successful. 
CR-6459, v4.0
Page 21 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
3.TARGETED STUDY POPULATION
3.1. General Characteristics 
Thetarget population for this study will be adult soft contact lens wearers between 18 and 3 9
years of age (inclusive) with m yopia and low astigmatism (suitable for correction with 
either -0.75 or -1.25 cylinder power) in both eyes. Note that the target population may
habitually wear sphere or toric lenses, solong as they meet the refractive eligibility criteria. 
3.2. Inclusion Cr iteria  
Potential subjects must satisfy of all the following criter ia to be enrolled in the study.
Inclusion Criteria following Screening
The subject must:
1.Read, understand, and sign the STATEMENT OF INFORMED CONSENT and receive a
fully executed copy of the form.
2.Appear able and willing to adhere to the instructions set forth in this clinical protocol.
3.Be between 18 and 3 9(inclusive) years of age at the tim e of screening.
4.By self -report, habitually wear soft contact lenses (sphere or toric) in both eyes in a daily
reusable or daily disposable wear modality (i.e. not extended wear modality). Habitual
wear is defined as a minimum of 6 hours of wear per day, fo r a minimum of 2 days per
week during the past 4 weeks .
5.Possess a wearable pair of spectacles that provide correction for distance vision .
Inclusion Criteria atBaseline Evaluation
The subject must:
6.In both eyes, h avemagnitude of the cylind ercomponent o f their vertex -corrected distance
refraction greater than or equal to 0.625 DC and less than 1.625 DC .
7.In both eyes, have themean spher eof their vertex -corrected distance refraction minus
half of the indicated contact lens label cylinder power be between -0.875 to -4.625 DS
(inclusive).
8.For each eye, h ave the cylinder axis of their distance refraction between 165° and 15°
(i.e., 180±15°, inclusive) or between 75° and 105° (i.e., 90±1 5°, inclusive).
9.For both eyes, have the sphere power of their habitual spectacles within ±0.50 Diopters
Sphere (DS) (inclusive) of the sphere power  of their current subjective refraction.
10.For both eyes, have the cylinder power of their habitual spectacle s within ±0.50 Diopters
Cylinder (DC) (inclusive) of the cylinder powe r of their current subjective refraction.
11.For both eyes, have the cylinder axis of their habitual spectacles within ±20° (inclusive)
of the cylinder axis of their current subjective refr action.
12.Achieve monocular VA of 20/30 or better with their habitual spectacles in both eyes.
CR-6459, v4.0
Page 22 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
3.3. Exclusion Criteria  
Potential subjects who meet any of the following criteria will be excluded from participating 
in the study: 
Exclusion Criteria following Screening
The subject must not:
1.Be currently pregnant or lactating.
2.Be diabetic.
3.Be currently using any ocular medications or have any ocular infection of any type.
4.By self -report, have any ocular or systemic disease, allergies, infection, or use of
medication that might contraindicate or interf ere with contact lens wear, or otherwise
compromise study endpoints, including infectious disease (e.g., hepatitis, tuberculo sis),
contagious immunosuppressive disease (e.g., Human Immunodeficiency Virus [ HIV]),
autoimmune disease (e.g. rheumatoid arthritis, Sjögren’s syndrome), or history of serious
mental illness or seizures. See section 9.1for additional details regarding excluded
systemic medications.
5.Have habitually worn rigid gas permeable (RGP) lenses, orthokeratology lenses, or
hybrid lenses (e.g. SynergEyes, SoftP erm) within the past 6 months.
6.Be currently wearing monovision or multifocal contact lenses.
7.Be currently wearing lenses in an extended wear modality.
8.Have a history of strabismus or amblyopia.
9.Be an employee (e.g., Investigator, Coordinator, Technician) o r immediate family
member of an employee (including partner, child, parent, grandparent, grandchild or
sibling of the employee or their spouse) of the clinical site.
10.Have participated in a contact lens or lens care product clinical trial within 7 days prio r to
study enrollment.
Exclusion Criteria atBaseline Evaluation
The subject must not:
11.Have clinically significant ( grade 3 or higher on the FDA grading scale) slit lamp
findings (e.g., corneal edema, neovascularizat ion or staining, tarsal abnormalities o r
bulbar injection) or other corneal or ocular  disease or abnormalities that contraindicate
contact lens wear or may otherwise compromise study endpoints (including entropion,
ectropion, chalazia, recurrent styes, glau coma, history of recurrent corneal ero sions,
aphakia, moderate or above corneal distortion, herpetic keratitis).
12.Have fluctuations in vision due to clinically significant dry eye or other ocular conditions.
13.Have had or have planned (within the study period) any ocular or intraocular surgery
(e.g., radial keratotomy, PRK, LASIK, iridotomy, retinal laser photocoagulation, etc.).
3.4. Enrollment Strategy  
Study subjects will be recruited from the Ins titution/clinical site’s subject database and/or 
utilizing Independent Ethics Committee (IEC) or Institutional Review Board (IRB) approved 
materials. 
CR-6459, v4.0
Page 23 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
4.STUDY DESIGN AND RATIONALE
4.1. Description of Study Design  
This will be a 5-visit, randomized, partially single -masked, bilateral wear, dispensing, 2 -
treatment × 2-period crossover study with spectacle -wear washout and wash -in periods .
Subject swill be randomized into one of twounique sequences to wear each contact le ns
correction one at a time (sphere followed by toric or toric followed by sphere sphere) .For 
each of the two wear periods, lenses will be worn bilaterally in a daily wear, daily disposable 
modality for 7(±2) days . Lenses will be worn for a minimum of 8 h ours per day on at least 5 
days of the wear period. There will be a 7(±2) day wash -in period prior to the first study lens 
wear period, and a 7(±2) day washout period between the first and second wear periods. 
During thew wash -in and washout periods, subje cts will only wear their own habitual 
spectacle correction (i.e., no contact lens wear). Subjective comfort, vision ,and handling will 
be assessed at fitting and follow -up visits for each contact lens wear period using the CLUE 
questionnaire , and CLUE visi on will also be assessed at the end of the washout period. 
HLHC VA and HLLC VA will be assessed with the study contact lenses at the 1 -week 
follow -up visits and with spectacle wear at the end of the washout period. At the final study 
visit, contact lens pr eference will be assessed (i.e., preference between the study contact 
lenses) as well as overall correction ranking (i.e., corrections ranked by preference 
considering both study lenses and habitual spectacles). Subjects will not have access to the 
study l enses following completion of the protocol.  
4.2. Study Design Rationale  
A crossover design was chosen for efficient comparison of the two study lenses with a
relatively small sample size , as this remove sinter-subject variance f rom the comparison.
Washout and wash -inperiod swith equal duration to the wear periods areincluded to reduce 
the potential for carryover effects and to allow comparison with the subject’s habitual 
spectacle correction. 
The AO1D and AO1DfA lenses were chosen as they have the same base material, and both 
have a history of commercial success. The CL UE questionnaire was selected on the basis of 
being the best available validated PRO tool for assessing subjective overall comf ort, vision 
and handling among the population of soft contact lens wearers. HLHC VA using ETDRS 
charts was included on the basis of this being the best available method for objectively 
assessing visual acuity. 
The investigational lenses will be fitted by optometrists who are experienced at fitting soft 
contact lenses and will be evaluated by habitual contact lens wearers in their standard 
wearing environment. 
4.3. Enrollment Target and Study Duration  
This study will have an enrollment target of 170subjects, with a target of at least 153to
complete. The study will be conducted at approximately 12clinical sites , where the 
enrollment target for each site will be approximately 14subjects. A subject will be 
considered enrolled upon signing of the informed cons ent form.  
CR-6459, v4.0
Page 24 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
There will be 5visits in total per subject; total st udy duration including the enrollment period 
is expected to be approximately 11weeks. Subjects who are discontinued prior to the final 
evaluation may b e replaced at the discretion of the stu dy sponsor .The investigation will end 
at the time that the study data is hard locked.
5.TEST ARTICLE ALLOCATION AND MASKING
5.1. Test Article Allocation 
This will be a randomized, partially subject -masked, 2×2 crossover study. Subjects will be 
randomized into one of 2 unique sequence groups in a 1:1 allocation ratio to wear 2 different 
study lenses one at a time bilaterally over 2 wear periods (AO1D followed by AO1DfA, or
AO1DfA followed by AO1D) .
Use of the test articles will be randomized using a randomization scheme supplied by the 
study biostatistician.  The randomized assignment of subjects will be performed at the first 
visit prior to the first fitting. C linical sites will follow the randomi zation scheme provided 
and will not pre -select or assign subjects. The following must have occurred prior to 
randomization:
xInformed consent must have been obtained
xThe subject must have met all inclusion and exclusion criteria
xThe subject history and base line information must have been collected
Randomly -permuted block randomization will be used  to avoid bias in the assignment of 
subjects to treatment and to enhance the validi ty of statistical comparisons across treatment 
groups.
When dispensing test art icles, the following steps should be followed to maintain 
randomization codes:
1.Investigator or designee (documented on the Delegation Log) will consult the
randomization scheme (lens fitting schedule) to obtain the test article assignment for
that subject prior to dispensing .
2.Investigator or designee will record the subject’s number on the appropriate line of
the randomization scheme (lens fitting schedule).
3.Investigator or designee will pull the appropri ate test articles from the study supply.
Alltest articles that are opened, whether dispensed (placed/fit on eye or dispensed
outside the clinical site) or not, must be  recorded on the Test Article Accountability
Log in the “Dispensed” section .
5.2. Masking  
This will be a partially single -masked trial; su bjects will notbe aware of the identity (i.e., 
brand) of the assigned lenses , however, they will be able to differentiate between the AO1D 
and AO1DfA lenses d ue to difference sin label powers, lens shape and scribe markings . Due 
to the different fitting p rocedure requirements for sphere a nd toric lenses, investigators and 
site staff will not be masked. 
CR-6459, v4.0
Page 25 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
5.3. Procedures for Maintaining and Breaking the Masking  
Two randomization codes (alphanumeric characters) will be generated, one for the AO1D 
lens and one for the AO1DfA lens, using the form . Study lenses will be supplied 
inblister packs label led with the study number, lot number, sphere power, expiration date 
and the randomization codes .Sponsor personnel involved in the conduct of the trial will not
be masked to the identity of study lenses.
When dispensing test articles, the following steps should be followed to maintain 
randomization codes:
1.Investigator or designee (documented on the Delegation Log) will consult the lens
fitting schedule to obt ain the test article assignment for that subject prior to
dispensing .
2.Investigator or designee will record the subject’s number on the appropriate line of
thelens fitting schedule.
3.Investigator or designee will pull the appropriate test ar ticles from the study supply.
All test articles that are opened, whethe r dispensed (placed/fit on eye or dispensed
outside the clinical site) or not, must be  recorded on the Test Article Accountability
Log in the “Dispensed” section .
Under normal circumstances, the mask should not be broken until all subjects have 
completed the study and the database is finali zed. Otherwise, the mask should be broken only 
if specific emergency treatment/course of action would be dictated by the subject knowing
theirtreatment status. In t he event the mask is broken, the sponsor must be informed as soon 
as possible. The date, time, and reason for th e unmasking must be documented in the subject 
record.
Subjects who have had their treatment assignm ent unmasked are expected to return for all 
remaining scheduled evaluations. If necessary, s ubjects who are discontinued may b e
replaced to reach the subject completion target. 
6.STUDY INTERVENTION
6.1. Identity of Test Articles  
Parameters for the test and control designs to be used in this study are sh own in the table 
below:
CR-6459, v4.0
Page 26 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Lens cases and fluorescein stri ps (either 0.6 mg or 1.0 mg) will be supplied for use as needed.
6.3. Administration of Test Articles  
Test articles will be dispensed to subject smeeting all eligibility requirements, including any 
dispensing requirements set forth in this clinical protocol. Subjects will be dispensed an 
adequate supply of test articles to comple te the study. Lost or damaged test articles may be 
replaced at the dis cretion of the investigator and/or the sponsor.
6.4. Packaging and Labeling  
The test articles will be packaged in blisters as the primary packaging. Lenses will be over -
labeled to mask subject sto the identity of the lens es.The sample study label sareshown
below:
Sample of Primary Packaging Secondary Packaging
CR-6459, v4.0
Page 28 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
6.5. Storage Conditions  
Test articles will be maintained at ambient temperat ures at the clinical site. Test articles must 
be kept under secure conditions.
6.6. Collection and Storage of Samples  
No samples will be collected as part of the study procedures. When possible, any lens or test 
article associated with an Adverse Event and/or a Product Quality Complaint must be 
retained and stored in a glass vial with moderate solution pending directions from the sponsor 
for potential return to JJVC.
6.7. Accountability of Test Articles  
JJVC will provide the Investigator with sufficient  quantities of study articles and supplies to 
complete the investigation. The Investigator is asked to retai n all lens shipment 
documentation for the test arti cle accountability records. 
Test article smust be kept in a locked storage cab inet, accessible only to those assigned by 
the Investigator for dispensing. The Investigator may delegate this activity to au thorized 
study site personnel listed on the Site Delegat ion Log. All test articles must be accounted. 
This includes:
1.What was dispensed for the subject for trial fitting, to wear out of the office, or issued
for the subject to replace appropriately between visits .
2.What was returned to the Investigator unused ,including expired or malfunctioning
product .
3.The number and reason for unplanned replacements .
The Investigator will collect all unused test articles from the subjects at the end of the 
subject’s participation. Subject returned unused test articles must be  separated from the 
clinical study inventory of un -dispensed test articles and must be labeled with the subject 
number and date of return . Following final reconciliation of test articles by the monitor, the 
Investigator or monitor will return all unused test articles to JJVC .
If there is a discrepancy between the shipment documents and the contents, contact the study 
monitor immediately .
CR-6459, v4.0
Page 29 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
1.14 Eligibility at baseline All responses to Inclusion Criteria questions 
must be answered “yes” and al l responses to 
Exclusion Criteria questions must be answered “no” for the subject to be considered eligible.
Note
: If:
xThe subject fails to meet baseline criteria
due to the power of their spectacle lenses
not being within the specified tolerance of
their current subjective refraction or their
VA with spectacles being worse than 20/30
in either eye (inclusion criterion 9, 10, 11
or 12), AND
xThe subjects best corrected monocularvisual acuity is 20/30 or better in botheyes, AND
xThe 
subject’s frame is suitable for updating
with new lenses*
Then offer to the subject that they may order 
new single vision distance lenses to be fitted 
in their current spectacle frame*, where the study sponsor will cover the cost of the new lenses. The subject may then return to repeat 
the baseline evaluation (one time) at a later 
date, after the updated spe
ctacles are 
dispensed. 
*Subjects may choose to purchase a new
spectacle frame (rather than updating the 
lenses in their existing frame ), however JJVC 
will only cover the cost of new lenses.
If subject is deemed to be ineligible at
baseline and would not meet eligibility 
criteria after having their spectacle lenses 
updated as described above, proceed to Final 
Evaluation. If the subject would meet the 
eligibility criteria after updating their spectacle lenses but chooses not to, mark ‘No’ on the Lens Fittin
g Prompt for the 
“eligible to return for another Baseline” and 
proceed to final evaluation. 
CR-6459, v4.0
Page 34 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
8.SUBJECTS COMPLETION/WITHDRAWAL
8.1. Completion Criteria  
Subjects are considered to have completed the study if they: 
xprovided informed consent .
xthey are eligible .
xhave not withdrawn/discontinued from the study for any reason described in section
8.2.
xcompleted all visits through the final visit (visit 5 ).
xIf all visits were completed but an additi onal visit is considered necessary for subject
care, follow the requirements for unscheduled vis itsin section 7.3.
8.2. Withdrawal/Discontinuation from the Study  
A subject will be withdrawn from the study for any of the following reasons:
xSubject withdrawal of consent .
xSubject not compliant to protocol .
xSubject lost to follow -up.
xSubject no longer meets eligibility criteria (e.g. the subject becomes pregnant) .
xSubject develops significant or serious adverse events necessitating discontinuation of
study lens wear .
xSubjects who have experienced a Corneal Infiltrative Event (CIE) .
xInvestigator’s clinical judgment regarding the subject safety reasons (that it is in the
best interest of the subject to stop treatment) .
xSubject misse sanystudy visits .
xSubject not compliant with study lens wear schedul e.
xSubject not successfully dispensed due to lack of efficacy and safety including poor
vision, poor comfort or unacceptable fit .
For discontinued subjects, the Investigator will:
xComplete the current visit (scheduled or unscheduled) .
xComplete the Final E valuation, indicating the reason that the subject was discontinued
from the study .
xRecord the spherocylindrical refraction with best corrected distance visual acuity .
xCollect used test article(s) (worn or brought to  the visit) from the subject and discard
them, unless otherwise stated in section 7.2.
xCollect all unused test article(s) from the subject .
xMake arrangements for subject care, if needed, due to their study participation
Additional subject smay be enrolled if a subject discontinues from the study prematurely. 
In cases where a subject is lost to follow -up, every possible effort must be made to contact 
the subject and determine the reason for discontinuation/withdrawal. The measures taken to 
follow up must be documented including two written attempts and a certified letter (or 
equivalent) as the final attempt. 
CR-6459, v4.0
Page 51 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
the treatment r egimen for the subject(s) and will disc uss this with the Investigator before any 
further subjects are enrolled.
The Sponsor will determine when a study will be stopped. The Principal Investigator always 
has the discretion to initiate stopping the study ba sed on patient safety or if information 
indicates the study’s results are compromised.
JJVC reserves the right to terminate the study at any time for any reason. Additionally, the 
IEC/IRB reserves the right to terminate the study if an unreasonable risk is determined. The 
study can be terminated by the Principal Investigator at the individual clinical site due to 
specific clinical observations, if in their opinion, after a discussion with JJVC, it is 
determined that it would be unwise to continue at the clinical site.
JJVC (and the IEC/IRB and DMC, if applicable) will evaluate all adverse events. If it is 
determined that an adverse event presents an unr easonable risk, the investigation, or that part 
of the investigation presenting the ri sk, will be terminated as soon as possible.
Should the study be terminated (either prematurely or as scheduled), the Investigator will 
notify the IEC/IRB and Regulatory Authority as required by local regulatory requirements.
12.PROCEDURE FOR HANDLING PRODUCT  QUALITY COMPLAINTS
A Product Quality Complaint (PQC) refers to any written, electronic, or oral communication 
that alleges deficiencies related to the iden tity, quality, durability, reliability, safety, 
effectiveness or performance of test articles after they have been released for clinical trial 
use.  
Potential complaints may come from a variety of sources including but not limited to 
subjects, clinical research associates (CRA),  clinical operations managers (COM), medical 
monitors, and site personnel, etc. The following are not considered product quality 
complaints:
xSubject satisfaction inquiries reported v ia “Subjective Questionnaires” and “Patient
Reported Outcomes (PRO) .”
xClinical test articles that are stored improperly or damaged after receipt at t he
investigational site .
xLens replacements that occur due to drops/fall -outs.
xDamage deemed by clinicians or clinical staff to be caused by handling by the user,
and not indicative of a quality deficiency (i.e. tears, rips, etc.), only in situations
where there is no deficiency alleged by the subject .
Within 24 hours of site personnel becoming aware that a PQC has occurred, the PQC must be 
recorded in the EDC system, which will tr igger an automatic email notification to the 
appropriate COM/CRA and Clinical QA representative. In cases where the EDC system in 
use is not configured to send automatic notifications or when an EDC system is not used, the 
COM/CRA is responsible for notifying Clinical QA upon discovery that a PQC has occurred.  
CR-6459, v4.0
Page 55 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Upon receipt of the EDC notification, the COM/CRA will contact the study site to collect 
additional information which will include: 
xDate the complaint was received/recorded in the EDC System (Date of Sponsor
Awareness) .
xWho received the complaint .
xStudy number .
xClinical site information (contact name, site ID, telephone number) .
xLot number(s) .
xUnique Subject Identifier(s) .
xIndication of who first observed complaint (site personnel or subject) .
xOD/OS indication, along with whether the lens was inserted .
xAny related AE number if applicable .
xDetailed complaint description (scheduled/unscheduled visit, wear time, symptoms,
resolution of symptoms, etc.) .
xEye Care Provider objective (sli t lamp) findings if applicable .
xConfirmation of pr oduct availability for return (and tracking information, if
available), or rationale if product is not available for return 
Once a complaint is received, it will be assessed by the COM, CRA, or trained site personnel 
to determine if it is an Adverse Event/Seri ous Adverse Event (AE/SAE). If the complaint 
results in an AE/SAE, the COM/CRA, or trained site personnel will follow section 13of this 
protocol. If the AE/SAE was potentially the re sult of a product qualit y related deficiency, 
these procedures also applies and will be executed in parallel.  
In some cases, a PQC form ma y be generated in EDC by the site in error. In this event, the 
PQC forms will be marked “Intentionally Left Bl ank” or “ILB”.  Justification for ILB must 
be documented.
13.ADVERSE EVENTS
13.1. Definitions and Classifications  
Adverse Event (AE) –An AE is “any untowa rd medical occurrence, unintended disease or 
injury, or untoward clinical signs (including abnormal laboratory findings) in subjects, users 
or other persons, whether or not related to  the investigational medical device. ”
Note :This definition includes events related to the investigational medical device or the 
comparator , and to the procedures involved .For users or other persons, this definition is 
restricted to events related to investigational medical devices .1
An AE includes any condition (including a pre -existing condition) that:
1.Was not present prior to the study, but appeared or reappeared following initiation of
the study .
CR-6459, v4.0
Page 56 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
2.Was present prior to the study but worsened during the study. This would include any
condition resulting from concomitant illnesse s, reactions to concomitant medications,
or progression of disease states .
Note : Pregnancy must be documented as an adverse event and must be reported to the 
clinical monitor and to the Sponsor immediately upon learning of the event.
Serious Adverse Event (SAE) –An SAE is any adverse event thatled to any of the 
following :
xDeath
xSerious deterioration in the health of the subject that resulted in any of the following:
xLife-threatening illness or injury
xPermanent or persistent impairment of a body structure or a body function
xHospitalization or prolongation of patient hospitalization
xMedical or surgical intervention to prevent life -threa tening illness or injury or
permanent impairment to a body structure or a body function.
xChronic disease
xFoetal distress, foetal death or a congenital physical or mental impairment of birth
defect.
Diagnoses and conditions that are considered Ocular Serious Adverse Events include, but not 
limited to:
xMicrobial Keratitis (MK)
xIritis (including cells in the anterior chamber)
xPermanent decrease in best spectacle correc ted visual acuity equivalent to 2 acuity
lines or greater
xCentral Corneal Opacity
xCentr al Corneal Neovascularization
xUveitis
xEndophthalmitis
xHypopyon
xHyphemia
xPenetration of Bowman’s Membrane
xPersistent Epithelial Defect
xLimbal cell Damage leading to Conjunctivalization
Significant Adverse Events –are defined as events that are symptomatic and warrant 
discontinuation (temporary or permanent) of the contact lens wear
Diagnoses and conditions that are considered Oc ular Significant Adverse Events include, but 
not limited to the following:
xContact Lens Induced Peripheral Ulcer (CLPU)
xSignificant Infiltrative Events (SIE)
xSuperior Epithelial Arcuate Lesions (SEALs)
CR-6459, v4.0
Page 57 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xAny Temporary Loss of > 2 Lines of BSCVA
xOther grade 3 or higher corneal findings, such as abrasions or edema
xNon-contact lens related corneal events -e.g. Epidemic Keratoco njunctivitis (EKC)
xAsymptomatic Corneal Scar
xAny corneal event which necessitates temporary lens discontinuation > 2 weeks
Non-Significant Adverse Events –are defined as those events that are usually 
asymptomatic and usually do not warrant discontinuatio n of contact lens wear but may cause 
a reduction in wear time.  However, the Invest igator may choose to prescribe treatment as a 
precautionary measure .
Diagnoses and conditions that are considered Ocular Non -Significant Adverse Events 
include, but not l imited to the following:
xNon-significant Infiltrative Event (NSIE)
xContact Lens Papillary Conjunctivitis (CLPC)
xSuperficial Punctate Keratitis (SPK)
xConjunctivitis: Bacterial, Viral, Allergic
xBlepharitis
xMeibomianitis
xContact Dermatitis
xLocalized Allergic Reactions
xAny corneal event not explicitly defined as serious or significant adverse event,
which necessitates temporary lens discontinuation < 2 weeks
Adverse Device Effect (ADE) –An ADE is an “adverse event related to the use of an 
investigational medi cal device. ”
NOTE 1:This definition includes  adverse events resultin g from insufficient or 
inadequate instructions for use, deployment, implantation, installation, or operation, or 
any malfunction of the investigational medical device.
NOTE 2:This defini tion includes any event resulting from use error or from intentional 
misuse of the investigational medical device.1
Unanticipated Adverse Device Effect (UADE) –A UADE is a ny serious adverse effect on 
health or safety or any life -threatening problem or death caused by, or associated with, the test 
article, if that effect, problem, or death was not previously identified in nature, severity, or 
degree of incidence in the investigational p lan, Investigator’s Brochure or protocol, or any 
other unanticipated serious problem  associated with the test artic le that relates to the rights, 
safety and welfare of subjects.
13.2. Assessing Adverse Events  
In conjunction with the medical monitor, the Investigator will evaluate adverse events to 
ensure the events are categorized correctl y. Elements of categorization will include:
xSeriousness/Classifications (see definition in section 13.1).
CR-6459, v4.0
Page 58 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xCausality or Relatedness –i.e. the relationship between the test article, study treatment
or study procedures and the adverse event (not r elated ,unlikely related ,possibly
related ,orrelated -see definition in section 13.2.1 ).
xAdverse Event Severity –Adverse event severity is used to assess the degree of
intensity of the adverse event (mild ,moderate ,orsevere -see definition in
section 13.2.2 ).
xOutcome –not recovered or not resolved ,recovering or resolving ,recovered or
resolved with sequelae ,recovered or resolved ,death related to adverse event , or
unknown .
xActions Taken –none ,temporarily discontinued ,permanently discontinued , orother .
13.2.1. Causality Assessment  
Causality As sessment –A determination of the relationship be tween an adverse event and the 
test article. The test article relationship for each  adverse event should be determined by the 
investigator using these explanations:
xNot Related -An adverse event that is not related to the use of the test article, study
treatment or study procedures .
xUnlikely Related –An adverse event for which an alternative explanation is more
likely, e.g. concomitant treatment, concomi tant disease(s), or the relationship of time
suggests t hat a causal relationship is not likely .
xPossibly Related –An adverse event that might be due to the use of the test article, or
to the study treatment or study procedures. An alternative explanation, e.g.
concomitant treatment, concomitant disease(s), is inconclusive. The relationship in
time is reasonable. Therefore, the causal relationship cannot be excluded .
xRelated –An adverse event that is listed as a possible adverse effect (device) or
adverse reaction (drug) and cannot be reasonably explained by a n alternative
explanation, e.g. concomitant treatment of c oncomitant disease(s). The relationship in
time is very suggestive, e.g. it is confirmed by de -challenge and re -challenge .
13.2.2. Severity Assessment  
Severity Assessment –A qualitative assessment of the d egree of intensity of an adverse 
event as determined by the Investigator or re ported to him/her by the subject. The assessment 
of severity is made irrespective of test article, study treatment or study procedure relationship 
or seriousness of the event and should be evaluated according to the following scale:
xMild –Event is noticeable to the subject but is easily tolerated and does not interfere
with the subject’s daily activities .
xModerate –Event is bothersome, possible requiring additional therapy, and may
interfere with the subject’s daily activities .
xSevere –Event is intolerable, necessitates additi onal therapy or alteration of therapy
and interferes with the subject’s daily activities .
13.3. Documentation and Follow -Up of Adverse Events  
The recording and d ocumenting of adverse events (ocular and non -ocular) begin when the 
subjects are exposed to the test article, study treatment or study procedure.  Adverse events 
CR-6459, v4.0
Page 59 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
reported before the use of test article, star t of study treatment, or study procedures will be
recorded as medical history. However, if the c ondition deteriorates at any time during the 
study it will be recorded and reported as an AE. Untoward medical events reported after the 
subject’s exit from the study will be recorded as adverse events at the discretion of the 
Investigator.
Upon finding an adverse event, the Principal Investigator will document the condition in the 
subject record and in the eCRFs andcomplete the Adverse Event eCRF.  
Complete descriptions of all adverse events mu st be available in the subject record. All 
Adverse Events including local and systemic reactions not meeting the criteria for “serious 
adverse events” shall be captured on the appropriate case report form or el ectronic data 
system. All adverse events occurring while the subject is enrolled in the study must be 
documented appropriately re gardless of relationship.  
It is the Investigator’s responsibility to maintain documentation of each reported adverse 
event. All adverse events will be followed in accordance with applicable licensing 
requirements. Such documentation will include the following:
xAdverse event (diagnosis not symptom) .
xDrawings or photographs (where appropriate) that detail the finding (e.g., size,
location, and depth, etc.) .
xDate the clinical site was notified .
xDate and time of onset .
xDate and time of resolution .
xAdverse event classification, severity, and relationship to test articles, as applicable .
xTreatment regimen instituted (where appropriate) , including concomitant medications
prescribed, in accordance with applicable licensing requirements .
xAny referral to another health care provider if needed .
xOutcome, ocular damage (if any) .
xLikely etiology .
xBest corrected visual acuity at the discovery of the event a nd upon conclusion of the
event , if the AE is related to the visual system .
Upon discovery of an AE that is deemed ‘possibly related ’or ‘related ’to the test article or 
study procedures (whether related to the visual system or no t), anAE review form 
must be completed .Additional dated and initialed entries should be made atfollow -up
evaluations .Separate forms must be completed for each eye if the AE is bilateral. 
In addition, if an infiltrate(s) is present, he/she will complete the Corneal Infiltrate 
Assessment eCRF. Where necessary, a culture of the corneal lesion will be collected to 
determine if the infection is microbial in nature. If cultures are collected, th e date of culture 
collection and laboratory util ized will be recorded. 
Changes in the severity of an AE shall be do cumented to allow an assessment of the duration 
of the event at each level of intensity to be performed. Adverse events characterized as 
CR-6459, v4.0
Page 60 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
intermittent require documentation of the onset an d duration of each episode. Changes in the 
assessment of relationship to the Test Article shall also be clearly documented.
Subjects who present with an adverse event shall be followed by the Investigator, w ithin 
licensure, until all signs and symptoms have returned to pre -treatment status, stabilized, or 
been satisfactorily resolved. If further treatm ent beyond licensure is required, the patient will 
be referred to the appropriate health care provider. The I nvestigator will use his/her clinical 
judgment as to whether a subject reporting with an adverse event will continue in the study. 
If a subject is discontinued from the study, it will be the responsibility of the Investigator to 
record the reason for disco ntinuation. The Investigator will also document the adverse event 
appropriately and complete the Adverse Event eCRF. Any subjects with ongoing adverse 
events related to the test article, study treatment or study procedures, as of the final study 
visit date , should be followed to resolution of the adverse event or until referral to an 
appropriate health care provider, as recommended by the Investigator. Non -ocular adverse 
events that are not related to the test article, study treatment, or study procedures m ay be 
recorded as “ongoing” without further follow -up.
13.4. Reporting Adverse Events 
The Investigator will notify the Sponsor of an adverse event by e -mail, facsimile, or 
telephone as soon as possible and no later than 24 hours from discovery for any serious 
/significant adverse events, and 2 days from discovery for any non -significant adverse event. 
In addition, a written report will be submitted by the Principal Investigator to the IEC/IRB 
according to their requirements ( section 13.4.2 ). The report will comment whether the
adverse event was considered to be related to the test article, study treatment or study 
procedures.
13.4.1. Reporting Adverse Events to Sponsor  
Serious/Significant Adverse Events
The Investigator will inform the sponsor of all serious/significant adverse events occurring 
during the study period as soon as possible by e -mail or telephone, but no later than 24 hours 
following discovery of th e event. The Investigator is obligated to pursue and obtain 
information requested by the Sponsor in addi tion to that information reported on the eCRF. 
All subjects experiencing a serious/significant  adverse event must be followed up and all 
outcomes must b e reported.
When medically necessary, the Investigator may break the randomization code to determine 
the identity of the treatment that the subject  received. The Sponsor and study monitor should 
be notified prior to unmasking the test articles.
In the ev ent of a serious/significant adverse event, the Investigator must:
xNotify the Sponsor immediately .
xObtain and maintain in the subject’s records all pertinent medical information and
medical judgment for colleagues who a ssisted in the treatment and follow -up of the
subject .
CR-6459, v4.0
Page 61 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
xProvide the Sponsor with a complete case  history which includes a statement as to
whether the event was or was not related to the use of the test article .
xNotify the IEC/IRB as required by the IEC/IRB reporting procedure according to
national regulations .
Unanticipated (Serious) Adverse Device Effect (UADE)
In the event of an Unanticipated (Serious) Adverse Device Effect (UADE), the Investigator 
will submit a report of the UADE to the Sponsor and IEC/IRB as soon as possible, but no 
later than 24 hours after the Investigator first learns of the effect. This report is in addition to 
the immediate notification mentioned above.
The Sponsor must conduct an evaluation of the UADE and must report the results of the 
evaluation to FDA, the IEC/IRB and participating Investigators within 10 working days after 
the Sponsor first receives notification of the effect.
Non-Serious Adverse Events
All non -serious adverse events, including non -serious adverse device effects, will be reported 
to the sponsor b y the Investigator no later than 2 days from discovery.
13.4.2. Reporting Adverse Events to the Responsible IEC/IRB and Health Authorities  
Adverse events that meet the IEC/IRB requirements for reporting must be reported within the 
IEC/IRB’s written guidelines. Eac h clinical site will refer to and follow any guidelines set 
forth by their Approving IEC/IRB. Each clinical site will refer to and follow any guidelines 
set forth by their local governing Health Authorities.
The Sponsor will report applicable Adverse Even ts to the local health authorities according 
the written guidelines, including reporting timelines. 
13.5. Event of Special Interest  
None.
13.6. Reporting of Pregnancy  
Subjects reporting pregnancy (by self -report) during the study will be discontinued after the 
event is recorded as an Adverse Event. Once discontinued, pregnant participants and their 
fetuses will not be monitored for study related purposes. Pregnant participants are not 
discontinued from contact lens or so lution related studies for safe ty concerns, but due to 
general concerns relating to pregnancy and contact lens use. Specifically, pregnant women 
are discontinued due to fluctuations in refractive error and/or visual acuity that occur 
secondary to systemic hormonal changes, and not due to unforeseen health risks to the 
mother or fetus.
CR-6459, v4.0
Page 62 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
14.STATISTICAL METHODS
14.1. General Considerations  
Statistical Analysis will be undertaken by the sponsor or under the authority of the sponsor. 
A general description of the statistic al methods to be implemented in this clinical trial is 
outlined below.
All data summaries and statistical analyses will be performed using the Statistical Analysis 
System ( SAS)software Version 9.4 or higher (SAS Institute, Cary, NC) . Throughout the
analysis of data, the results for each subject /eye will be used when available for 
summarization and statistical analysis. Unscheduled visits will be summarized separately and 
will be excluded from the statistical analysis.
Summary tables (descriptive statistics and/or frequency tables) will be provided for all 
baseline variables, efficacy variables and safety variables as appropriate. Continuous 
variables will be summarized with descriptive statistics (n, mean, s tandard deviation (SD), 
median, minimum and maximum). Frequency count and percentage of subjects or eyes 
within each category will be provided for categorical data.
14.2. Sample Size Justification  
The plan is to enroll 170 subjects with a target of at least 153 subjects to complete. No
historical 2 by 2 crossover study was available to estimate the treatment difference of the 
primary and secondary endpoints between the Te st (AO1DfA) and the Control (AO1D) on 
the study population . The Visual Performance HLHC logM ARand Contact Lens Preference 
from  between 1-Day ACUVUE®Moist Astigmatism and 1 -Day ACUVUE®Moist 
were summarized in Table 7.These estimates are used as references to estimate the power for 
the primary hypothesis inTable 8and for the third secondary hypothesis (S3) in Table 11.
Due to the lack of historical data, several scenarios are enumerated to estimate the power for 
the first secondary hypothesis (S1) in Table 9and similarly for second secondary hypothesis 
(S2) in Table 10. Scenarios with above 80% power is highlighted in blue. The power 
calculation swereconducted with paired t test for the primary, first and second secondary 
hypotheses; and with Pearson’s chi -square test for the third hypothesis using the POWER 
procedure in SAS 9.4 .
Table 7: Historical Data from 
Endpoint N Subjects 1-Day
ACUVUE®Moist
for Astigmatism1-Day
ACUVUE®
Moist Intraclass 
Correlation
Visual Performance 
(HLHC logMAR)72 Mean (SD)
-0.09 (0.08)Mean (SD)
-0.02 (0.09)0.399
Contact Lens 
Preference72 N (%)
49 (68.1%)N (%)
17 (23.6%)-
CR-6459, v4.0
Page 63 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
14.6. Secondary Analys es 
The secondary analyses will be conducted on Intent -to-Treat populations to establish 
superiority and Per -protocol populations for non -inferiority.
CLUE Vision score –(S1)
CLUE vision scores at 1 -week follow -up will be analyzed using a linear mixed effect model. 
This model will include the experimental design factors: sequence of lens wear, lens wearing 
period, lens type and the interaction between lens type and lens wearing period as fixed 
effects. Baseline characteristics known of importance such as age andgender will be 
included as fixed covariate s.Site will be included as random effects (G -side) .The covariance 
of residuals between of the same subject (R -side) across period will be modeled using either 
homogenous compound symmetry (CS) or unstructured (UN) covariance structure. The 
structure that returns the lowest finite sample corrected Akaike’s Information criterion10will 
be selected as the structure that best fits the model. The Kenward and Roger met hod will be 
used for the calculation of the denominator degree of freedom11.
The null and alternative hypotheses for superiority ofCLUE Vision for the Test (AO1DfA) 
minus Control (AO1D) is asfollows:
ܪ0: Δ ≤ 0.0
ܣܪ :Δ>0.0
where Δ is the least-square means (LSM) difference between the T est and Control lens (Test 
minus Control). Superiority for the Test to the Control lens will be established on ITT 
population ifthe lower bound of the 95% two-sided confidence interval (CI) for least square s
mean (LSM) difference (Test -Control) of CLUE Vision score isgreater than 0 .
Visual Performance (HLHC logMAR) –(S2)
The comparison of Monocular distance visual performance of HLHC in logMAR scale
between the Test (AO1DfA) to the Control (Spectacles) will be analyzed using a similar 
linear mixed effect model described in the primary analysis above. Since this endpoint for the 
Test lens (AO1DfA) will be collected before or after the Control (Spectacles) and no 
carryover effect is expected in objective v isual performance, the lens wearing period can be 
defined accordingly.    
The null and alternative hypotheses for non -inferiority of Test lens (AO1DfA) relative to 
Control (Spectacles) are as follows:
ܪ0: Δ > 0.05
ܣܪ :Δ ≤ 0.05
where Δ is the mean difference in logMAR between Test lens and Control lens (Test minus 
Control).  Non -inferiority will be declared on Per -protocol population if the upper bound of 
the(1-α) two -sided confidence interval of the mean difference between Tes t and Control is 
less than 0.05. The α  is the Type I error derived from Gatekeeping strategy and α-
propagation in Section 14.4.  If the non -inferiority is established, superiority will be declared 
CR-6459, v4.0
Page 67 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
if the upper bound of the confidence interval of the mean d ifference between Test and 
Control is less than 0.0.
Contact Lens Preference –(S3)
Contact lens preference question will be analyzed using a baseline -category logistic model ,
where the response of the Control lens preference is the baseline category .Thismodel will 
include the experimental design factors: sequen ce of lens wear, lens wearing period, lens 
type and the interaction between lens type and lens wearing period as fixed effects. Baseline 
characteristics known of importance such as age andgende rwill be included as fixed 
covariate s.
The null and alternative hypotheses for superiority of Test (AO1DfA) lens relative to Control
(AO1D) are as follows:
ܪ0: Δ ≤ 1.0
ܣܪ :Δ>1.0
where Δ is the odds of the preference for the Test to the preference for the Control (Test 
divided by Control). Superiority for the Test to the Control lens will be established on ITT 
population ifthe lower bound of the (1-α) %two-sided confidence interval (CI) for least 
squares mean (LSM) odds (Test di vided by Control) of the contact lens preference isgreater
than 1.0. The α is the Type I error derived from Gatekeeping strategy and α-propagation in 
Section 14.4.
14.7. Other Exploratory Analys is 
Not applicable.
14.8. Interim Analysis  
Not applicable.
14.9. Procedure for Handling Missing Data and Drop -Outs  
Missing or spurious values will not be imputed. The count of missing values will be included 
in the summary tables and listings. 
14.10. Procedure for Reporting Deviations from Statistical Plan  
The analysis will be conducted according to that specified in above sections. There are no 
known reasons for which it is planned to devi ate from these analysis methods. If for any 
reason a change is made, the change will  be documented in the study report along with a 
justification for the change.
CR-6459, v4.0
Page 68 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
15.DATA HANDLING AND RECORD KEEPING/ARCHIVING
15.1. Electronic Case Report Form/Data Collection  
The data for this study will be captured on electronic case report forms (eCRFs) using the
BioClinica EDC system. An authorized data originator will enter study data into the eCRFs 
using the EDC system. Data collected on equipment that is not captured in EDC will be 
formatted to the specification of the JJVC database manager and sent to JJVC for analysis. 
No e xternal datasources will be included in this study.
The clinical data will be recorded on dedica ted eCRFs specifically designed to match the 
study procedures for each visit. Only specifically delegated staff can enter data on a CRF.  
Once completed, the eCRFs will be reviewed for accuracy and completeness and signed by 
the Investigator. The sponsor or sponsor’s representatives will be authorized to gain access to 
the subject recordation for the purposes of monitoring and auditing the study. 
Edit checks, electronic queries, an d audit trails are built into the system to ensure accurate 
and complete data collection. Data will be tran smitted from the clinical site to a secure 
central database as forms are completed or updated, ensuring information accuracy, security, 
and confident iality. After the final database lock, the Investigator will be provided with 
Individual Patient Profiles (IPP) including the full audit trail on electronic media in PDF 
format for all of the study data. The IPP must be retained in the study files as a cer tified copy 
of the source data for the study. 
The content and structure of the eCRFs are compliant with ISO14155:20 20.1
15.2. Subject Record  
At a minim um, subject record should be available for the following: 
xsubject identification
xeligibility
xstudy identification
xstudy discussion
xprovision of and date of informed consent
xvisit dates
xresults of safety and efficacy parameters as required by the protocol
xa record of all adverse events
xfollow -up of adverse events
xmedical history and concomitant medication
xtest article receipt/dispensing/return records
xdate of study completion
xreason for early discontinuation of test article or withdrawal from the study, if
applicable
CR-6459, v4.0
Page 69 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
The subject record is the eCRF or an external record. The author of an entry in the subject 
record must be identifiable. The first point of entry is considered to be the source record.
Adverse event notes must be reviewed and initial ed by the Investigator.
15.3. Trial Registration on ClinicalTrials.gov  
This study will be registered on ClinicalTrials.gov by the Sponsor.
16.DATA MANAGEMENT
16.1. Access to Source Data/Document  
The Investigator/Institution will permit trial -related monitoring, audits, IEC/IRB review and 
regulatory inspection(s) by providing direct access to source data/documents. Should the 
clinical site be contacted for an audit by an IEC/IRB or regulatory authority, JJVC must be 
contacted and notified in writing wi thin 24 hours.
16.2. Confidentiality of Information  
Information concerning the investigational product and patent application processes, 
scientific data or other pertinent information is confidential and remains the property of 
JJVC. The Investigator may use thi s information for the purposes of the study only. It is 
understood by the Investigator that JJVC will use information developed in this clinical study 
in connection with the development of the investigational product and therefore may disclose 
it as requir ed to other clinical investigators and to regulatory agencies. In order to allow the 
use of the information derived from this clinical study, the Investigator understands that 
he/she has an obligation to provide comp lete test results and all data developed during this 
study to the Sponsor.
16.3. Data Quality Assurance  
Steps will be taken to ensure the accuracy and reliability of data, include the selection of 
qualified investigators and appropriate clinical si tes and review of protocol procedures with 
the Princip al Investigator. The Principal Investigator, in turn, must ensure that all Sub -
Investigators and clinical site personnel are familiar with the protocol and all study -specific 
procedures and have appropriate knowledge of the study article.
Training on case report form completion will be provided to clinical site personnel before the 
start of the study. The Sponsor will review case  report forms for accuracy and completeness 
remotely during the conduct of the study, during monitoring visits, and after transmi ssion to 
data management. Any data discrepancies will be resolved with the Investigator or designee, 
as appropriate.
Quality Assurance representatives from JJVC may visit clinical sites to review data produced 
during the study and to access compliance wit h applicable regulations pertaining to the 
conduct of clinical trials. The clinical sites  will provide direct access to study -related source 
CR-6459, v4.0
Page 70 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
data/documents and reports for the purpose of  monitoring and auditing by JJVC and for 
inspection by local and regul atory authorities.
16.4. Data Monitoring Committee  (DMC)  
Not applicable for this study. 
17.CLINICAL MONITORING
The study monitors will maintain close contact with the Principal Investigator and the 
Investigator’s designated clinical site personnel. The monitor’s responsibilities will include:
xEnsuring that the investigation is bei ng conducted according to the protocol, any
subsequent versions , and regulatory requirements are maintained .
xEnsuring the rights and wellbeing of subjects are protected .
xEnsurin g adequate resources, including facilities, laboratories, equipment, and
qualified clinical site personnel .
xEnsuring that protocol deviations are documen ted with corrective action plans, as
applicable .
xEnsuring that the clinical site has sufficient test ar ticle and supplies .
xClarifying questions regarding the study .
xResolving study issues or problems that may arise .
xReviewing of study records and source documentation veri fication in accordance with
the monitoring plan .
18.ETHICAL AND REGULATORY ASPECTS
18.1. Study -Specific Design Considerations  
Potential subjects will be fully informed of the risks and requirements of the study and, 
during the study, subjects will be given any new information that may affect their decision to 
continue participation. Subjects will be told that their consent to participate in the study is 
voluntary and may be withdrawn at any time with no reason given and without penalty or 
loss of benefits to which they  would otherwise be entitled. Subjects will only be enrolled if 
thefully able to un derstand the risks, benefits, and potential adverse events of the study and
provide their consent voluntarily .
18.2. Investigator Responsibility  
The Principal Investigator is responsible for ensuring that the clinical study is performed in 
accordance with the signed agree ment, the investigational plan, section 4 of the ICH E6 (R2)
guidelines on Good Clinical Practice (GCP) ,2and applicable regulatory requirements. GCP is 
an international ethical and scientific quali ty standard for designing, conducting, recording, 
and reporting studies that in volve the participation of human subjects. Compliance with this 
standard provides public assurance that the rights, safety, and well -being of study subjects are 
protected, consistent with the principles of the Declaration of Helsinki 64th WMA General 
Assem bly 20133 and that the clinical study data are credible. The Investigator must maintain 
CR-6459, v4.0
Page 71 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
clinical study files in accordance with section 8 of the ICH E6 (R2) guidelines on Good 
Clinical Practice (GCP) ,2and applicable regulatory requirements.
18.3. Independent Ethics Committee or Institutional Review Board (IEC/IRB)  
Before the start of the study, the Investigator (or Sponsor when applicable) will provide the 
IEC/IRB with current and complete copies of  the following documents (where applicable):
xFinal protocol .
xSponsor -approved informed consent form (and any other written materials to be
provided to the subjects)
xInvestigator’s Brochure (or equivalent information) .
xSponsor -approved subject recruitment materials .
xInformation on compensation for study -related injuries or payment to subjects for
participation in the study .
xInvestigator’s curriculum vitae, clinical licenses, or equivalent information (unless
not required, as documented by IEC/IRB) .
xInformation regarding funding, name of the Sponsor, institutional affiliations, other
potential conflicts of interest, and incentives for subjects .
xAny other documents that the IEC/IRB requests to fulfill its obligation .
This study will be undertaken only after IEC/IRB has given full approval of the final 
protocol, the informed consent form, applicable recruitin g materials, and subject 
compensation programs, and the Sponsor has receive d a copy of this approval. This approval 
letter must be dated and must clearly identify the documents being approved.
During the study, the Investigator (or Sponsor when applicable ) will send the following 
documents to the IEC/IRB for their review and approval, where appropriate:
xProtocol revisions
xRevision(s) to informed consent form and any other written materials to be provided
to subjects
xIf applicable, new or revised subject re cruitment materials approved by the Sponsor
xRevisions to compensation for study -related injuries or payment to subjects for
participation in the study
xInvestigator’s Brochure revisions
xSummaries of the status of the study (at least annually or at interval s stipulated in
guidelines of the IEC/IRB)
xReports of adverse events that are serious, unanticipated, and associated with the test
articles, according to the IRB’s requirements
xNew information that may adversely affect the safety of the subjects or the con duct of
the study
xMajor protocol deviations as required by the IEC/IRB
xReport of deaths of subjects under the Investigator's care
xNotification if a new Investigator is res ponsible for the study at the clinical site
xAny other requirements of the IEC/IRB
CR-6459, v4.0
Page 72 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
For protocol revisions that increase subject risk, the revisions and applicable informed 
consent form revisions must be submitted promptly to the IEC/IRB for review and approval 
before implementation of the change(s).
At least once a year, the IEC/IRB will review and reapprove this clinical study. This request 
should be documented in writing.
At the end of the study, the Investigator (or Sponsor where required) will notify the IEC/IRB 
about the study completion. Documentation of this notification must be re tained at the 
clinical site and a copy provided to the CRO or Sponsor as applicable.
18.4. Informed Consent  
Each subject or their representative, must give written consent according to local 
requirements after the nature of the study has be en fully explained. The consent form must be 
signed before performance of any study -related activity. The consent form that is used must 
be approved by both the S ponsor and by the reviewing IEC/IRB. The informed consent is in 
accordance with principles that originated in the Declaration of Helsinki,3current ICH GCP2
andISO 14155 :20201guidelines, applicable regulatory requirements, and Sponsor Policy.
Before entry into the study, the Investigator or an authorized member of the clinical site 
personnel must explain to poten tial subject the aims, met hods, reasonably anticipated 
benefits, and potential hazards of the study, and any discomfort it may entail. Subjects will be 
informed that their participation is voluntary and that they may withdraw consent to 
participate at any time. 
The subject will be given sufficient time to read the informed consent form and the 
opportunity to ask questions. After this explan ation and before entry into the study, consent 
should be appropriately recorded by means of the subject's dated signa ture. After having 
obtained the consent, a copy of the informed consent form must be given to the subject.
18.5. Privacy of Personal Data  
The collection, processing and disclosure of pers onal data and medical information related to 
the Study Subject, and persona l data related to Principal Investigator and any clinical site 
personnel (e.g., name, clinic address and phone number, curriculum vitae) is subject to 
compliance with the Health Information P ortability and Accountability Act (HIPAA)4and 
other applicable personal data protection and security laws and regulations. Appropriate 
measures will be employed to safeguard these data, to maintain the confident iality of the 
person’s related health and medical information, to properly inform the concerned persons 
about the collection and processing of their person al data, to grant them reasonable access to 
their personal data and to prevent access by unauthorized persons.
All information obtained during the course of the investigation will be regarded as 
confidential. All personal data gath ered in this trial will be treated in strictest confidence by 
Investigators, monitors, Sponsor’s personnel and IEC/IRB. No da ta will be disclosed to any 
third party without the express permission of th e subject concerned, with the exception of 
CR-6459, v4.0
Page 73 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
Sponsor personnel (monitor, auditor), IEC/IRB and regulatory organizations in the context of 
their investigation related activities that, as part of the investigation will have access to the 
CRFs and subject records.
The collection and processing of personal data from subjects enrolled in this study will be 
limited to those data that are necessary to  investigate the efficacy, safety, quali ty, and utility 
of the investigational product(s) used in this study.
These data must be collected and processed with adequate precautions to ensure 
confidentiality and compliance with applicable data privacy protection laws and regulations.
The Sponsor e nsures that the personal data will be:
xprocessed fairly and lawfully .
xcollected for specified, explicit, and legiti mate purposes and not further processed in a
way incompatible with these purposes .
xadequate, relevant, and not excessive in relation to said purposes .
xaccurate and, where necessary, kept current .
Explicit consent for the processing of personal data will be obtained from the participating 
subject before collection of data. Such consent should also address the transfer of the data to 
other entit ies and to other countries.
The subject has the right to request through the Investigator access to his personal data and 
the right to request rectificati on of any data that are not correct or complete. Reasonable steps 
should be taken to respond to such a request, taking into consideration the nature of the 
request, the conditions of the study, and the applicable laws and regulations.
Appropriate technical and organizational measures to protect the personal data against 
unauthorized disclosures or access , accidental or unlawful destruction, or accidental loss or 
alteration must be put in place. Sponsor pers onnel whose responsibilities require access to 
personal data agree to keep the identity of study subjects confidential .
19.STUDY RECORD RETENTION
In compliance with the ICH GCP guidelines ,2the Investigator/Institution will maintain all 
CRFs and all subject records that support the data collected from each subject, as well as all 
study documents as specified in ICH GCP2and all study documents as specified by the 
applicable regulatory requi rement(s). The Investigator/Institution will take measures to 
prevent accidental or premature destruction of these documents.
Essential documents must be retained until at least two ( 2)years after the last approval of a 
marketing application in an ICH region and until there are no pending or contemplated 
marketing applications in an ICH region or until at least two (2) years have elapsed since the 
formal discontinuation of clinical devel opment of the investigational product. These 
documents will be retained for a longer period if required by the applicable regulatory 
CR-6459, v4.0
Page 74 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
requirements or instructed by the Sponsor. It is the responsibility of the Sponsor to inform the 
Investigator/Institution a s to when these documents no longer need to be retained.
If the responsible Investigator retires, relocates, or for other reasons withdraws from the 
responsibility of keeping the study records, custody must be transferred to a person who will 
accept the r esponsibility. The Sponsor must be notified in writing of the name and address of 
the new custodian.  Under no circumstance shall the Investigator relocate or dispose of any 
study documents before having obtained written approval from the Sponsor.
If it be comes necessary for the Sponsor or the appropriate regulatory authority to review any 
documentation relating to this study, the Investigator must permit access to such reports.
If the Investigator has a question regarding retention of study records, he/sh e should contact 
JJVC.
20.FINANCIAL CONSIDERATIONS
Remuneration for study services and expenses w ill be set forth in detail in the Clinical 
Research Agreement. The Research Agreement will be signed by the Principal Investigator 
and a JJVC management represent ative prior to study initiation.
JJVC reserves the right to withhold remuneration for costs associated with protocol 
violations such as:
xContinuing an ineligible subject in the study .
xScheduling a study visit outside the subject’s acceptable visit range .
JJVC reserves the right to withhold final remuneration until all study related activities have 
been completed, such as:
xQuery resolution .
xCase Report Form signature .
xCompletion of any follow -up action items .
21.PUBLICATION
Outcomes of this study may be publi shed, at the discretion of the study Sponsor. 
22.REFERENCES
.
1.ISO 14155:20 20: Clinical Investigation of Medical Devices for Human Subjects —
Good Clinical Practice. Available at: https://www.iso.org/standard/71690.html
2.International Council for Harmonization Good Clinical Practice E6 (R2) (ICH GCP).
Available at: https://www.ich.org/page/efficacy -guidelines
3.Declaration of Helsinki -Ethical principles for Medical Research Involving Human
Subjects. Available at: https://www.wma.net/policies -post/wma -declaration -of-
helsinki -ethical -principles -for-medical -research -involving -human -subjects/
CR-6459, v4.0
Page 75 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
4.United States (US) Co de of Federal Regulations (CFR). Available at:
https://www.gpo.gov/fdsys/browse/collecti onCfr.action?collectionCode=CFR
5.Morgan, P. B., Woods, C. A., Tranoudis, I. O., Efron, N., Jones, L., Aighamdi, W., et
al. (2019). International Contact Lens Prescribin g in 2018. Contact Lens Spectrum ,
34(1), 26 –32.
6.Taneri, S., Arba -Mosquera, S., Rost, A., Kießler, S., & Dick, H. B. (2020).
Repeatability and reproducib ility of manifest refraction. Journal of Cataract &
Refractive Surgery ,46(12), 1659 -1666.
7.Osborn Loren z, K. Clinical Report #( ) Toric Eye Strain and
Stability (TESS ).February 1 , 201 6.
8.Wirth RJ, Edwards MC, Henderson M , et al. Development of the contact lens user
experience: CLUE scales. Optometry and Vision Science . 2016; 93.8:801.
9.Health Information Portability and Accountability Act (HIPAA). Available at:
https://www.hhs.gov/hipaa/for -professionals/privacy/index.html
10.Keselman HJ, Algina J, Kowalchuk RK, Wolfinger RD. A comparison of two
approaches for selecting covariance structur es in the analysis of repeated
measurements. Communications in Statistics -Simulation and Computation.
1998;27(3):591 -604.
11.Kenward MG, Roger JH. Small Sample Infe rence for Fixed Effects from Restricted
Maximum Likelihood. Biometrics. 1997;53(3):983.
12.Bretz, F., Posch, M., Glimm, E., Klinglmueller, F., Maurer, W., & Rohmeyer, K.
(2011). Graphical approaches for multiple comparison procedures using weighted
Bonferroni, Simes, or parametric tests. Biometrical Journal, 53(6), 894 -913.
CR-6459, v4.0
Page 76 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX A: PATIENT REPORTED OUTCOMES (STUDY QUESTIONNAIRES)  
CR-6459, v4.0
Page 77 of 200JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 1
CR-6459, v4.0
Page 78 of 200JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 2
CR-6459, v4.0
Page 79 of 200JJVC CONFIDENTIAL
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 3
Page 80 of 200
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 4
Page 81 of 200
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 5
Page 82 of 200
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 6
Page 83 of 200
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 7
Page 84 of 200
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 8
Page 85 of 200
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 9
Page 86 of 200
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 10
Page 87 of 200
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 11
Page 88 of 200
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 12
Page 89 of 200
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 13
Page 90 of 200
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 14
Page 91 of 200
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 15
Page 92 of 200
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 16
Page 93 of 200
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 17
Page 94 of 200
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 18
Page 95 of 200
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 19
Page 96 of 200
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 20
Page 97 of 200
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 21
Page 98 of 200
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 22
Page 99 of 200
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 23
Page 100 of 200
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 24
Page 101 of 200
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 25
Page 102 of 200
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 26
Page 103 of 200
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 27
Page 104 of 200
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 28
Page 105 of 200
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 29
Page 106 of 200
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 30
Page 107 of 200
35263(&,),&$7,219HUVLRQ)LQDO3URWRFRO-RKQVRQ	-RKQVRQ9LVLRQ&DUH,QF&RQILGHQWLDO 31
Page 108 of 200
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX B: PATIENT INSTRUCTION GUIDE   
A Patient Instruction Guide ( PIG) will be provided separately .
Page 109 of 200
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX C: PACKAGE INSERT (APPROVED PRODUCT)  
Page 110 of 200
DESCRIPTION
ACUVUE OASYS® Brand Contact Lenses 1-Day and ACUVUE OASYS® 
Brand Contact Lenses 1-Day for ASTIGMATISM are soft (hydrophilic) 
contact lenses made with HydraLuxe™ Technology. They are available as spherical or toric lenses respectively. 
These lenses are made of a silicone hydrogel material containing an internal 
wetting agent, visibility tint, and UV absorbing monomer and are tinted blue using Reactive Blue Dye #4 to make the lenses more visible for handling.
A benzotriazole UV absorbing monomer is used to block UV radiation. The 
transmittance characteristics for these lenses are less than 1% in the UVB range of 280 nm to 315 nm and less than 10% in the UVA range of 316 nm to 380 nm 
for the entire power range.
Lens Properties:
The physical/optical properties of the lens are:
• Speciﬁ  c Gravity (calculated): 0.98 - 1.12
• Refractive Index: 1.42
• Light Transmission: 85% minimum• Surface Character: Hydrophilic• Water Content: 38%
• Oxygen Permeability:
VALUE METHOD
122 x 10
-11 (cm2/sec) 
(ml O2/ml x mm Hg) at 35°CFatt (boundary corrected, non-
edge corrected)
103 x 10-11 (cm2/sec) 
(ml O2/ml x mm Hg) at 35°CFatt (boundary corrected, edge corrected)
Lens Parameters:
• Diameter Range: 12.0 mm to 15.0 mm
• Center Thickness: varies with power
• Base Curve Range: 7.85 mm to 10.00 mm
• Spherical Power Range: -20.00D to +20.00D
• Cylinder Power Range: .25D to -10.00D
• Axis Range: 2.5° to 180°Page 113 of 200
AVAILABLE LENS PARAMETERS
ACUVUE OASYS® Brand 1-Day with HydraLuxe™ Technology are 
hemispherical shells of the following dimensions:
Diameter: 14.3 mm
Center Thickness: 0.085 mm to 0.221 mm (varies with power)
Base Curve: 8.5 mm, 9.0 mm
Powers: -0.50D to -6.00D (in 0.25D increments)
-6.50D to -12.00D (in 0.50D increments)+0.50D to +6.00D (in 0.25D increments)+6.50D to +8.00D (in 0.50D increments)
ACUVUE OASYS® Brand 1-Day with HydraLuxe™ Technology for 
ASTIGMATISM  are hemitoric shells of the following dimensions:
Diameter: 14.3 mm
Center Thickness: 0.075 mm to 0.172 mm (varies with power)
Base Curve: 8.5 mm
Powers: +0.00D to -6.00D (in 0.25D increments)
Cylinders: -0.75D, -1.25D, -1.75D, -2.25D*Axis: 10° to 180° in 10° increments
*-2.25D cylinder is availble in 10°, 20°, 70°, 80°, 90°, 100°, 110°, 
160°, 170°, 180° axes only.
+0.25D to +4.00D (in 0.25D increments)
-6.50D to -9.00D (in 0.50D increments)Cylinders: -0.75D, -1.25D, -1.75DAxis: 10°, 20°, 70°, 80°, 90°, 100°, 110°, 160°, 
170°, 180°
Page 114 of 200
• Corneal hypoesthesia (reduced corneal sensitivity).
• Any systemic disease that may affect the eye or be exaggerated by 
wearing contact lenses.
• Allergic reactions of ocular surfaces or adnexa that may be induced 
or exaggerated by wearing contact lenses or use of contact lens 
solutions.
• Ocular irritation due to allergic reactions which may be caused by 
use of contact lens solutions (i.e., rewetting drops) that contain chemicals or preservatives (such as mercury, Thimerosal, etc.) to which some people may develop an allergic response.
• Any active corneal infection (bacterial, fungal, protozoal, or viral).
• If eyes become red or irritated.
WARNINGS
Patients should be advised of the following warnings pertaining to 
contact lens wear:
EYE PROBLEMS, INCLUDING CORNEAL ULCERS, CAN DEVELOP 
RAPIDLY AND LEAD TO LOSS OF VISION; IF THE PATIENT EXPE-RIENCES:
• Eye Discomfort,
• Excessive Tearing,• Vision Changes,• Loss of Vision,• Eye Redness,• Or Other Eye Problems, 
THE PATIENT SHOULD BE INSTRUCTED TO IMMEDIATELY RE-
MOVE THE LENSES AND PROMPTLY CONTACT THE EYE CARE PROFESSIONAL.
• When prescribed for daily wear, patients should be instructed not 
to wear lenses while sleeping. Clinical studies have shown that 
the risk of serious advers  is increased when lenses are worn overnight, and that the risk of ulcerative keratitis is greater for 
Page 
extended wear contact lens users than for daily wear users.3
• Studies have shown that contact lens wearers who are smokers 
have a higher incidence of adverse reactions than nonsmokers.
• Problems with contact lenses or lens care products could result in 
serious injury to the eye. Patients should be cautioned that proper 
use and care of contact lenses and lens care products are essential for the safe use of these products.
• The overall risk of ulcerative keratitis may be reduced by carefully 
following directions for lens care.
3 New England Journal of Medicine, September 21, 1989; 321 (12), pp. 773-783
Speciﬁ  c Instructions for Use and Warnings:
• Water Activity
Instructions for Use
Do not expose contact lenses to water while wearing them.WARNING:
Water can harbor microorganisms that can lead to severe infection, vision loss or blindness. If lenses have been submersed in water when participating in water sports or swimming in pools, hot tubs, lakes, or oceans, the patient should be instructed to discard them and replace them with a new pair. The Eye Care Professional should be consulted for recommendations regarding wearing lenses during any activity involving water.
PRECAUTIONS
Special Precautions for Eye Care Professionals:
• Due to the small number of patients enrolled in clinical investiga-
tion of lenses, all refractive powers, design conﬁ  gurations, or lens parameters available in the lens material are not evaluated in signif-icant numbers. Consequently, when selecting an appropriate lens design and parameters, the Eye Care Professional should consider all characteristics of the lens that can affect lens performance and ocular health, including oxygen permeability, wettability, central and peripheral thickness, and  diameter.
P1 8 0
• The potential impact of these factors on the patient’s ocular health 
should be carefully weighed against the patient’s need for refractive 
correction; therefore, the continuing ocular health of the patient and lens performance on the eye should be carefully monitored by the prescribing Eye Care Professional.
• Patients who wear these lenses to correct presbyopia using mono-
vision may not achieve the best corrected visual acuity for either far or near vision. Visual requirements vary with the individual and should be considered when selecting the most appropriate type of lens for each patient.
• Fluorescein, a yellow dye, should not be used while the lenses are 
on the eyes. The lenses absorb this dye and become discolored. Whenever ﬂ  uorescein is used in eyes, the eyes should be ﬂ  ushed with a sterile saline solution that is recommended for in-eye use.
• Eye Care Professionals should instruct the patient to remove the 
lenses immediately if the eyes become red or irritated. 
Eye Care Professionals should carefully instruct patients about the following care regimen and safety precautions.
Handling Precautions:
• Before leaving the Eye Care Professional’s ofﬁ  ce, the patient should 
be able to promptly remove the lenses or should have someone 
else available who can remove the lenses for him or her. 
• DO NOT use if the sterile blister package is opened or damaged. 
• Always wash and rinse hands before handling lenses. Do not get 
cosmetics, lotions, soaps, creams, deodorants, or sprays in the 
eyes or on the lenses. It is best to put on lenses before putting on makeup. Water-based cosmetics are less likely to damage lenses than oil-based products. 
• DO NOT touch contact lenses with the ﬁ  ngers or hands if the 
hands are not free of foreign materials, as microscopic scratches of the lenses may occur, causing distorted vision and/or injury to the eye.
• Carefully follow the handli r n, removal, and wearing 
instructions in the “Patient Instruction Guide” for the prescribed 
Page 119 of 200
wearing schedule and those prescribed by the Eye Care 
Professional.
• Always handle lenses carefully and avoid dropping them.
• Never use tweezers or other tools to remove lenses from the lens 
container unless speciﬁ  cally indicated for that use. Slide the lens up 
the side of the bowl until it is free of the container. 
• Do not touch the lens with ﬁ  ngernails. 
Lens Wearing Precautions:
• If the lens sticks (stops moving) on the eye, follow the recom-
mended directions in “Care for a Sticking (Non-Moving) Lens." The lens should move freely on the eye for the continued health of the eye. If non-movement of the lens continues, the patient should be instructed to immediately consult his or her Eye Care Professional.
• Never wear lenses beyond the period recommended by the Eye 
Care Professional.
• The patient should be advised to never allow anyone else to wear 
their lenses. They have been prescribed to ﬁ  t their eyes and to correct their vision to the degree necessary. Sharing lenses greatly increases the chance of eye infections.
• If aerosol products, such as hair spray, are used while wearing 
lenses, exercise caution and keep eyes closed until the spray has settled.
• Avoid all harmful or irritating vapors and fumes while wearing 
lenses. 
• Always discard lenses worn as prescribed by the Eye Care 
Professional. 
Lens Care Precautions:  
• The patient should be informed that no cleaning or disinfection is 
needed when lenses are worn for daily disposable wear.  Patients should always dispose of lenses when removed and have spare lenses or spectacles available.
Page 120 of 200
Other Topics to Discuss with Patients:
• Always contact the Eye Care Professional before using any medi-
cine in the eyes. 
• Certain medications, such as antihistamines, decongestants, 
diuretics, muscle relaxants, tranquilizers, and those for motion 
sickness may cause dryness of the eye, increased lens awareness, or blurred vision. Should such conditions exist, proper remedial measures should be prescribed. Depending on the severity, this could include the use of lubricating drops that are indicated for use with soft contact lenses or the temporary discontinuance of contact lens wear while such medication is being used. 
• Oral contraceptive users could develop visual changes or changes 
in lens tolerance when using contact lenses. Patients should be cautioned accordingly. 
• As with any contact lens, follow-up visits are necessary to assure 
the continuing health of the patient’s eyes. The patient should be instructed as to a recommended follow-up schedule. 
Who Should Know That the Patient is Wearing Contact Lenses?
• Patients should inform all doctors (Health Care Professionals) about 
being a contact lens wearer. 
• Patients should always inform their employer of being a contact 
lens wearer. Some jobs may require use of eye protection equip-ment or may require that the patient not wear contact lenses. 
ADVERSE REACTIONS
The patient should be informed that the following problems may occur when wearing contact lenses:
• The eye may burn, sting, and/or itch.
• There may be less comfort than when the lens was ﬁ  rst placed on 
the eye.
• There may be a feeling of something in the eye (foreign body, 
scratched area).
• There may be the potential for some temporary impairment due to Page 121 of 200
peripheral inﬁ  ltrates, peripheral corneal ulcers, or corneal erosion. 
There may be the potential for other physiological observations, such as local or generalized edema, corneal neovascularization, corneal staining, injection, tarsal abnormalities, iritis, and conjuncti-vitis; some of which are clinically acceptable in low amounts.
• There may be excessive watering, unusual eye secretions, or 
redness of the eye.
• Poor visual acuity, blurred vision, rainbows, or halos around 
objects, photophobia, or dry eyes may also occur if the lenses are worn continuously or for too long a time.
The patient should be instructed to conduct a simple 3-part self-examina-tion at least once a day. They should ask themselves:
• How do the lenses feel on my eyes?
• How do my eyes look?• Have I noticed a change in my vision? 
If the patient reports any problems, he or she should be instructed to 
IMMEDIATELY REMOVE THE LENS. If the problem or discomfort stops, the patient should discard the lens and place a new fresh lens on the eye.
If after inserting the new lens, the problem continues, the patient should be 
directed to IMMEDIATELY REMOVE THE LENS AND CONTACT HIS OR HER EYE CARE PROFESSIONAL.
The patient should be instructed NOT to use a new lens as self-treatment 
for the problem.
The patient should be advised that when any of the above symptoms oc-
cur, a serious condition such as infection, corneal ulcer, neovascularization, or iritis may be present. He or she should be instructed to seek immediate professional identiﬁ  cation of the problem and prompt treatment to avoid serious eye damage.
Page 122 of 200
GENERAL FITTING GUIDELINES
A. Patient Selection
Patients selected to wear these lenses should be chosen based on: 
• Motivation to wear lenses 
• Ability to follow instructions regarding lens wear care
• General health 
• Ability to adequately handle and care for the lenses 
• Ability to understand the risk and beneﬁ  ts of lens wear
Patients who do not meet the above criteria should not be provided with 
contact lenses. 
B. Pre-ﬁ  tting Examination
Initial evaluation of the patient should begin with a thorough case history 
to determine if there are any contraindications to contact lens wear. During 
the case history, the patient’s visual needs and expectations should be 
determined as well as an assessment of their overall ocular, physical, and 
mental health. 
Preceding the initial selection of trial contact lenses, a comprehensive 
ocular evaluation should be performed that includes, but is not limited to, 
the measurement of distance and near visual acuity, distance and near 
refractive prescription (including determining the preferred reading distance 
for presbyopes), keratometry, and biomicroscopic evaluation. 
Based on this evaluation, if it is determined that the patient is eligible to 
wear these lenses, the Eye Care Professional should proceed to the lens 
ﬁ  tting instructions as outlined below. 
C. Initial Power Determination
A spectacle refraction should be performed to establish the patient’s 
baseline refractive status and to guide in the selection of the appropriate 
lens power. Remember to compensate for vertex distance if the refraction 
is greater than ±4.00D.
D. Base Curve Selection (Trial Lens Fitting)
The following trial lenses should be selected for patients regardless of kera-
tometry readings. However, corneal curvature measurements should be 
performed to establish the patient’s baseline ocular status.  
Page 123 of 200
Example 1
Diagnostic lens: -2.00DSpherical over-refraction: -0.25D
Final lens power: -2.25D
Example 2
Diagnostic lens: -2.00DSpherical over-refraction: +0.25D
Final lens power: -1.75D
If vision is acceptable, perform a slit lamp examination to assess adequate 
ﬁ  t (centration and movement). If the ﬁ  t is acceptable, dispense the lenses and instruct the patient to return in one week for reassessment (see dispensing and follow up information in PATIENT MANAGEMENT).
All patients should be supplied with a copy of the PATIENT 
INSTRUCTION GUIDE for these lenses. Copies are available for download at www.acuvue.com.
TORIC FITTING GUIDELINES
Although most aspects of the ﬁ  tting procedure are identical for all types 
of soft contact lenses, including toric lenses, there are some additional steps and/or rules to follow to assure the proper ﬁ  t of toric lenses.
The only new steps you must follow in prescribing ACUVUE
 OASYS® 
1-Day for ASTIGMATISM are that you must determine the stability, 
repeatability, and drift angle of the lens axis so that you can prescribe the correct lens axis for the patient.
A. How to Determine Lens Cylinder and Axis Orientation 
1. Locate the Orientation Marks
To help determine the proper orientation of the toric lens, you’ll 
ﬁ  nd two primary marks approximately 1 mm from the lens edge representing the vertical position on opposite ends of the lens at 6 and 12 o’clock (Fig. 1). Because of the lens’ ballasting system, either mark can represent the vertical position – there is no “top” and “bottom” as in a prism-ballasted lens. You don’t need to view both marks to assess orientation; simply look for the 6 o’clock mark as you would with - llasted lens.
Page 125 of 200
Figure 1
You’ll need a slit lamp biomicroscope with a 1 to 2 mm 
parallelepiped beam to highlight the marks when the lens is ﬁ  tted to the eye. There are a number of techniques you can use to improve the visibility of the 6 o’clock mark. Using a parallelepiped beam and medium magniﬁ  cation (10x or 15x), slowly pan down the lens, looking just below the direct illumination at the retroilluminated area. Backlighting the mark this way should make it more visible. Sometimes manipulating the lower lid may be necessary to uncover the mark.
2. Observe Lens Rotation and Stability
Observe the position and stability of the “bottom” mark. It usually stabilizes at the 6 o’clock position. If it does, calculation of the lens power will be straightforward. The 6 o’clock position is not a “must”; however, the absolute requirement is that the axis position be stable and repeatable.
The mark may stabilize somewhat left or right (drift) of the vertical 
meridian and still enable you to ﬁ  t a toric lens for that eye, as long as the lens always returns to the same “drift axis” position after settling. The deviation can be compensated for in the ﬁ  nal prescription. Your objective is to ensure that whatever position the initial lens assumes near 6 o’clock, this position must be stable and repeatable. With full eye movement or heavy blink, you may see the marks swing away, but they must return quickly to the original stable position. If the lens does not return quickly, you may need to select a different lens.
3. Assessing Rotation
Imagine the eye as a clock dial and every hour represents a 30° interval. If the orientation mark of the initial lens stabilizes somewhat left or right of the vertical position, the ﬁ  nal lens will orient on the eye with the same deviation. You can use an axis reticule in the slit lamp or use a line-scribed lens in a spectacle trial frame to measure or estimate the “drift angle” of the cylinder axis.
To compensate for this “drift”, measure or estimate the “drift”, then 
add or subtract it from the refractive axis to determine the correct cylinder axis. Use the LARS (Left Add, Right Subtract) method to determine which direction to compensate.
Page 126 of 200
B. Final Lens Power 
When the diagnostic lens has its axis aligned in the same meridian 
as the patient’s refractive axis, a spherocylindrical over-refraction may be performed and visual acuity determined. However, in the case of crossed axes, such as when the diagnostic lens axis is different from the spectacle cylinder axis, it is not advisable to perform a full spherocylindrical over-refraction because of the difﬁ  culty in computing the resultant power. A spherical over-refraction without cylinder refraction may be performed. 
If the required cylinder correction falls between two available cylinder 
powers, it is recommended to prescribe the lower cylinder power lens. See below for instructions on how to determine the ﬁ  nal lens power.
1. For the Sphere
If sphere alone or combined sphere and cylinder Rx > ±4.00D, 
compensate for vertex distance. If sphere alone or combined sphere and cylinder Rx ≤ ±4.00D, vertex compensation is not necessary.
2. For the Cylinder
Adjust the axis by the drift angle using the LARS method. Choose a cylinder that is ≤ 0.50D from the refractive cylinder.
3. Case Examples
Example 1
Manifest (spectacle) refraction:
O.D. -2.50D / -1.25D x 180° 20/20O.S. -2.00D / -1.00D x 180° 20/20
Choose a diagnostic lens for each eye with axis 180°. Place 
the lens on each eye and allow a minimum of 3 minutes for it to equilibrate, based on the patient’s initial response to the lens. If the lens has not yet stabilized, recheck until stable.
Check the orientation of the axis mark. If the bottom axis mark 
is in the 6 o’clock position on both eyes, choose the appropriate cylinder as listed previously. If the lens has not yet stabilized, recheck until stable.
Here is the Rx Prescribed:
O.D. -2.50D / -1.25D x 180°O.S. -2.00D / -0.75D x 180°
Page 127 of 200
Example 2
Manifest (spectacle) refraction:O.D. -3.00D / -1.00D x 90° 20/20O.S. -4.75D / -2.00D x 90° 20/20
Choose diagnostic lenses of -3.00D / -0.75D x 90° for the right 
eye and -4.50D / -1.75D x 90° for the left eye, the nearest lenses available to the spherical power, cylinder power, and axis needed. For the left eye, since the manifest refraction called for -4.75D, compensating for vertex distance the sphere is reduced by 0.25D to -4.50D. The cylinder power will be -1.75D. Place the lens on each eye and allow a minimum of 3 minutes for it to equilibrate, based on the patient's initial response to the lens. If the lens has not yet stabilized, recheck until stable. 
Right Eye
The orientation mark on the right lens rotates left from the 6 
o’clock position by 10° and remains stable in this position. Compensation for this rotation should be done as follows: 
Compensate the 10° axis drift by adding it to the manifest 
refraction axis.
Here is the Rx Prescribed:
O.D. -3.00D / -0.75D x 100°
Left Eye
The orientation mark on the left lens rotates right from the 6 
o’clock position by 10° and remains stable in this position. 
Compensate for the 10° axis drift by subtracting it from the 
manifest refraction axis. 
Here is the Rx Prescribed: 
O.S. -4.50D / -1.75D x 80°
If vision is acceptable, perform a slit lamp examination to assess 
adequate ﬁ  t (centration and movement). If ﬁ  t is acceptable, dispense the lenses instructing the patient to return in one week for reassessment (see dispensing and follow-up information in PATIENT MANAGEMENT).
All patients should be supplied with a copy of the PATIENT INSTRUCTION GUIDE for these lenses. Copies are available for download at www.acuvue.com.
Page 128 of 200
MONOVISION FITTING GUIDELINES
A. Patient Selection
1. Monovision Needs Assessment
For a good prognosis, the patient should have adequately 
corrected distance and near visual acuity in each eye. The amblyopic patient or the patient with signiﬁ  cant astigmatism (greater than 1.00D) in one eye may not be a good candidate for monovision correction with these lenses.
Occupational and environmental visual demands should be 
considered. If the patient requires critical vision (visual acuity and stereopsis), it should be determined by trial whether this patient can function adequately with monovision correction. Monovision contact lens wear may not be optimal for activities such as:
• visually demanding situations such as operating potentially 
dangerous machinery or performing other potentially hazardous 
activities; and
• driving automobiles (e.g., driving at night). Patients who cannot 
meet state driver's licensing requirements with monovision correction should be advised to not drive with this correction, OR may require that additional over-correction be prescribed.
2. Patient Education
All patients do not function equally well with monovision correc-tion. Patients may not perform as well for certain tasks with this correction as they have with spectacles (multifocal, bifocal, trifocal, readers, progressives). Each patient should understand that monovision, as well as other presbyopic alternatives, can create a vision compromise that may reduce visual acuity and depth perception for distance and near tasks. Therefore, caution should be exercised when the patient is wearing the correction for the ﬁ  rst time until they are familiar with the vision provided in visually chal-lenging environments (e.g., reading a menu in a dim restaurant, driving at night in rainy/foggy conditions, etc.). During the ﬁ  tting process, it is necessary for the patient to realize the disadvantages as well as the advantages of clear near vision and straight ahead and upward gaze that monovision contact lenses provide.
Page 129 of 200
B. Eye Selection
1. Ocular Preference Determination Methods
Generally, the non-dominant eye is corrected for near vision. The 
following two methods for eye dominance can be used.
Method 1:  Determine which eye is the “sighting eye.” Have the 
patient point to an object at the far end of the room. 
Cover one eye. If the patient is still pointing directly at the object, the eye being used is the dominant (sighting) eye.
Method 2:  Determine which eye will accept the added power with 
the least reduction in vision. Place a hand-held trial lens equal to the spectacle near ADD in front of one eye and then the other while the distance refractive error correction is in place for both eyes. Determine whether the patient functions best with the near ADD lens over the right or left eye.
2. Other Eye Selection Methods
Other methods include the "Refractive Error Method" and the "Visual Demands Method."
Refractive Error MethodFor anisometropic correction, it is generally best to ﬁ  t the more 
hyperopic (less myopic) eye for distance and the more myopic (less hyperopic) eye for near.
Visual Demands Method
Consider the patient’s occupation during the eye selection process 
to determine the critical vision requirements. If a patient’s gaze for near tasks is usually in one direction, correct the eye on that side for near.
Example: A secretary who places copy to the left side of the desk 
will function best with the near lens on the left eye.
C. Special Fitting Characteristics
1. Unilateral Vision Correction
There are circumstances where only one contact lens is required. As an example, an   would only require a near 
lens, whereas a bilateral myope would require corrective lenses on 
CR-6459, v4.0
Page 130 of 200JJVC CONFIDENTIAL
both eyes.
Examples: A presbyopic emmetropic patient who requires a +1.75D ADD 
would have a +1.75D lens on the near eye and the other eye left without correction. 
A presbyopic patient requiring a +1.50D ADD who is -2.50D 
myopic in the right eye and -1.50D myopic in the left eye may have the right eye corrected for distance and the left uncorrected for near.
2. Near ADD Determination
Always prescribe the lens power for the near eye that provides optimal near acuity at the midpoint of the patient’s habitual reading distance. However, when more than one power provides optimal reading performance, prescribe the least plus (most minus) of the powers.
3. Trial Lens Fitting
A trial ﬁ  tting is performed in the ofﬁ  ce to allow the patient to experience monovision correction. Lenses are ﬁ  t according to the GENERAL FITTING GUIDELINES for base curve selection described in this Package Insert.
Case history and standard clinical evaluation procedure should 
be used to determine the prognosis. Determine the distance correction and the near correction. Next determine the near ADD. With trial lenses of the proper power in place, observe the reaction to this mode of correction.
Allow the lenses to settle for about 20 minutes with the correct 
power lenses in place. Walk across the room and have the patient look at you. Assess the patient’s reaction to distance vision under these circumstances. Then have the patient look at familiar near objects such as a watch face or ﬁ  ngernails. Again assess the reaction. As the patient continues to look around the room at both near and distance objects, observe the reactions. Only after these vision tests are completed should the patient be asked to read print. Evaluate the patient’s reaction to large print (e.g., typewritten copy) at ﬁ  rst and then graduate to newsprint and ﬁ  nally smaller type sizes.
After the patient’s perform u er the above conditions 
is completed, tests of vis ac it and reading ability under 
CR-6459, v4.0
Page 131 of 200JJVC CONFIDENTIAL
Recommended Follow-up Examination Schedule (complications 
and speciﬁ  c problems should be managed on an individual patient 
basis):
1. One week from the initial lens dispensing to patient
2. One month post-dispensing
3. Every three to six months thereafter 
NOTE: Preferably, at the follow-up visits, lenses should be worn for at least 
six hours.
Recommended Procedures for Follow-up Visits:
1. Solicit and record patient’s symptoms, if any.
2. Measure visual acuity monocularly and binocularly at distance and 
near with the contact lenses.
3. Perform an over-refraction at distance and near to check for residual 
refractive error.
4. With the biomicroscope, judge the lens ﬁ  tting characteristics (as 
described in the GENERAL FITTING GUIDELINES) and evaluate 
the lens surface for deposits and damage.
5. Following lens removal, examine the cornea and conjunctiva with 
the biomicroscope and ﬂ  uorescein (unless contraindicated).
• The presence of vertical corneal striae in the posterior central 
cornea and/or corneal neovascularization is indicative of 
excessive corneal edema.
• The presence of corneal staining and/or limbal-conjunctival 
hyperemia can be indicative of an unclean lens, a reaction to solution preservatives, excessive lens wear and/or a poorly ﬁ  tting lens.
• Papillary conjunctival changes may be indicative of an unclean 
and/or damaged lens.
6. Periodically perform keratometry and spectacle refractions. The 
values should be recorded and compared to the baseline meas-
urements.
If any observations are abnormal, use professional judgment to 
alleviate the problem and restore the eye to optimal conditions. If CR-6459, v4.0  
Page 134 of 200JJVC CONFIDENTIAL
the criteria for successful ﬁ  t are not satisﬁ  ed during any follow-up 
examinations, repeat the patient’s trial ﬁ  tting procedure and reﬁ  t 
the patient.
WEARING SCHEDULE
The wearing schedule should be determined by the Eye Care Professional.   
Regular checkups, as determined by the Eye Care Professional, are also extremely important.
Patients tend to overwear the lenses initially. The Eye Care Professional 
should emphasize the importance of adhering to the initial maximum wear-ing schedule.  Maximum wearing time should be determined by the Eye Care Professional based upon the patient’s physiological eye condition, because individual response to contact lenses varies.
The maximum suggested wearing time for these lenses is:
Day Hours
1 6-8
2 8-10
3 10-12
4 12-14
5 and after all waking hours
REPLACEMENT SCHEDULE
These lenses are indicated for daily disposable wear and should be 
discarded upon removal.
LENS CARE DIRECTIONS
When lenses are prescribed for daily disposable wear, the Eye Care Professional should provide the patient with appropriate and adequate warnings and instructions for daily disposable lens wear at the time they are dispensed. 
CR-6459, v4.0
Page 135 of 200JJVC CONFIDENTIAL
The Eye Care Professional should review with patients that no cleaning 
or disinfection is needed with daily disposable lenses. Patients should always dispose of lenses when they are removed and have spare lenses or spectacles available.
Basic Instructions
• Always wash, rinse, and dry hands before handling contact lenses.
• Do not use saliva or anything other than the recommended solutions 
for lubricating or rewetting lenses. Do not put lenses in the mouth.
• Eye Care Professionals may recommend a lubricating/rewetting solution which can be used to wet (lubricate) lenses while they are being worn to make them more comfortable. 
Care for a Sticking (Non-Moving) Lens
If the lens sticks (stops moving), the patient should be instructed to apply 
a few drops of the recommended lubricating or rewetting solution directly to the eye and wait until the lens begins to move freely on the eye before removing it. If non-movement of the lens continues after a few minutes, the patient should immediately consult the Eye Care Professional.
EMERGENCIES
The patient should be informed that if chemicals of any kind (household products, gardening solutions, laboratory chemicals, etc.) are splashed into the eyes, the patient should: FLUSH EYES IMMEDIATELY WITH TAP WATER AND IMMEDIATELY CONTACT THE EYE CARE PROFESSIONAL OR VISIT A HOSPITAL EMERGENCY ROOM WITHOUT DELAY. 
HOW SUPPLIED
Each UV-blocking sterile lens is supplied in a foil-sealed plastic package containing buffered saline solution with methyl ether cellulose. The plastic package is marked with the following: 
• ACUVUE OASYS
® 1-Day: base curve, power, diameter, lot number, 
and expiration date
• ACUVUE OASYS® 1-Day MATISM: base curve, power, 
diameter, cylinder, axis, lot and expiration dateCR-6459, v4.0
Page 136 of 200JJVC CONFIDENTIAL
REPORTING OF ADVERSE REACTIONS
All serious adverse experiences and adverse reactions observed in 
patients wearing these lenses or experienced with these lenses should be reported to:
Johnson & Johnson Vision Care, Inc.
7500 Centurion Parkway
Jacksonville, FL 32256
USA
Tel: 1-800-843-2020
www.acuvue.com
CR-6459, v4.0
Page 137 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX D:  
x LENS FITTING CHARACTERISTICS
x  SUBJECT REPORTED OCULAR SYMPTOMS
x  DETERMINATION OF DISTANCE SPHEROCYLINDRICAL
REFRACTIONS
x  BIOMICROSCOPY SCALE
x DISTANCE AND NEAR VISUAL ACUITY EVALUATION
x TORIC FIT EVALUATION
x ETDRS DISTANCE VISUAL ACUITY MEASURMENT PROCEDURE
x  PATIENT REPORTED OUTCOMES
x  LENS INSERTION AND REMOVAL
x VISUAL ACUITY CHART LUMINANCE AND ROOM ILLU MINATION
TESTING
CR-6459, v4.0
Page 139 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
 LENS FITTING CHARACTERISTICS  
 
CR-6459, v4.0
Page 140 of 200JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number :  Revi sion Number:  6
Page 1of 5CR-6459, v4.0
Page 141 of 200JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number :  Revi sion Number:  6
Page 2of 5            
       
CR-6459, v4.0
Page 142 of 200JJVC CONFIDENTIAL
Title:                          Lens Fitting Characteristics
Document Type:  
Document Number :  Revi sion Number:  6
Page 3of 5CR-6459, v4.0
Page 143 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
 SUBJECT REPORTED OCULAR OUTCOMES  
 
CR-6459, v4.0
Page 146 of 200JJVC CONFIDENTIAL
Title:                         Subject Reported Ocular Symptoms/Problems
Document Type:  
Document Number :  Revi sion Number:  4
Page 1of 1  
  
            
CR-6459, v4.0
Page 147 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
 DETERMINATION OF DISTANCE SPHEROCYLINDRICAL 
REFRACTIONS  
CR-6459, v4.0
Page 148 of 200JJVC CONFIDENTIAL
Title:                        Determination of Dist ance Spherocylindrical Refractive Error
Document Type:  
Document Number :  Revi sion Number:  5
Page 1of 5  
CR-6459, v4.0
Page 149 of 200JJVC CONFIDENTIAL
Title:                        Determination of Dist ance Spherocylindrical Refractive Error
Document Type:  
Document Number :  Revi sion Number:  5
Page 2of 5CR-6459, v4.0
Page 150 of 200JJVC CONFIDENTIAL
Title:                        Determination of Dist ance Spherocylindrical Refractive Error
Document Type:  
Document Number :  Revi sion Number:  5
Page 3of 5CR-6459, v4.0
Page 151 of 200JJVC CONFIDENTIAL
Title:                        Determination of Dist ance Spherocylindrical Refractive Error
Document Type:  
Document Number :  Revi sion Number:  5
Page 4of 5CR-6459, v4.0
Page 152 of 200JJVC CONFIDENTIAL
Title:                        Determination of Dist ance Spherocylindrical Refractive Error
Document Type:  
Document Number :  Revi sion Number:  5
Page 5of 5CR-6459, v4.0
Page 153 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
BIOMICROSCOPY SCALE  
 
CR-6459, v4.0
Page 154 of 200JJVC CONFIDENTIAL
Title: Biomicroscopy Scale
Document Type:
Document Number: Revision Number:  10
CR-6459, v4.0
Page 155 of 200JJVC CONFIDENTIAL
Title: Biomicroscopy Scale
Document Type:
Document Number: Revision Number:  10
CR-6459, v4.0
Page 156 of 200JJVC CONFIDENTIAL
Title: Biomicroscopy Scale
Document Type:
Document Number: Revision Number:  10
CR-6459, v4.0
Page 157 of 200JJVC CONFIDENTIAL
Title: Biomicroscopy Scale
Document Type:
Document Number: Revision Number:  10
  
CR-6459, v4.0
Page 159 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
DISTANCE AND NEAR VISUAL ACUITY EVALUATION  
CR-6459, v4.0
Page 160 of 200JJVC CONFIDENTIAL
Title:                        Distance and Near Snellen Visual Acuity Evaluation
Document Type:  
Document Number :  Revi sion Number:  5
Page 1of 4  
CR-6459, v4.0
Page 161 of 200JJVC CONFIDENTIAL
Title:                        Distance and Near Snellen Visual Acuity Evaluation
Document Type:  
Document Number :  Revi sion Number:  5
Page 2of 4CR-6459, v4.0
Page 162 of 200JJVC CONFIDENTIAL
Title:                        Distance and Near Snellen Visual Acuity Evaluation
Document Type:  
Document Number :  Revi sion Number:  5
Page 3of 4CR-6459, v4.0
Page 163 of 200JJVC CONFIDENTIAL
Title:                        Distance and Near Snellen Visual Acuity Evaluation
Document Type:  
Document Number :  Revi sion Number:  5
Page 4of 4CR-6459, v4.0
Page 164 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
TORIC FIT EVALUATION  
CR-6459, v4.0
Page 165 of 200JJVC CONFIDENTIAL
Title:                          Toric Fit Evaluation
Document Type:  
Document Number :  Revi sion Number:  7
Page 1of 4CR-6459, v4.0
Page 166 of 200JJVC CONFIDENTIAL
Title:                          Toric Fit Evaluation
Document Type:  
Document Number :  Revi sion Number:  7
Page 2of 4CR-6459, v4.0
Page 167 of 200JJVC CONFIDENTIAL
Title:                          Toric Fit Evaluation
Document Type:  
Document Number :  Revi sion Number:  7
Page 3of 4 
CR-6459, v4.0
Page 168 of 200JJVC CONFIDENTIAL
Title:                          Toric Fit Evaluation
Document Type:  
Document Number :  Revi sion Number:  7
Page 4of 4CR-6459, v4.0
Page 169 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
ETDRS DISTANCE VISUAL ACUITY MEASUREMENT PROCEDURE  
CR-6459, v4.0
Page 170 of 200JJVC CONFIDENTIAL
Title: Distance LogMAR Visual Acuity Measurement Procedure 
Document Type:  
Document Number:   Revision Number: 5 
 
         
CR-6459, v4.0
Page 171 of 200JJVC CONFIDENTIAL
Title: Distance LogMAR Visual Acuity Measurement Procedure 
Document Type:  
Document Number:   Revision Number: 5 
 
  
CR-6459, v4.0
Page 172 of 200JJVC CONFIDENTIAL
Title: Distance LogMAR Visual Acuity Measurement Procedure 
Document Type:  
Document Number:   Revision Number: 5 
 
  
CR-6459, v4.0
Page 173 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
 PATIENT REPORTED OUTCOMES  
 
CR-6459, v4.0
Page 174 of 200JJVC CONFIDENTIAL
Title: Patient Reported Outcomes
Document Type:
Document Number: Revision Number: 3
Page 1of 1                      
CR-6459, v4.0
Page 175 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
 LENS INSERTION AND REMOVAL  
 
CR-6459, v4.0
Page 176 of 200JJVC CONFIDENTIAL
Title:   Lens Insertion and Removal
Document Type:
Document Number : Revi sion Number:  3
Page 1of 2CR-6459, v4.0
Page 177 of 200JJVC CONFIDENTIAL
Title:   Lens Insertion and Removal
Document Type:
Document Number : Revi sion Number:  3
Page 2of 2CR-6459, v4.0
Page 178 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
 VISUAL ACUITY CHART LUMINANC E AND ROOM ILLUMINATION 
TESTING  
 
CR-6459, v4.0
Page 179 of 200JJVC CONFIDENTIAL
Title:                        Visual Acuity Chart Luminance and Room Illumination Testing
Document Type:  
Document Number :  Revi sion Number:  4
Page 1of 8CR-6459, v4.0
Page 180 of 200JJVC CONFIDENTIAL
Title:                        Visual Acuity Chart Luminance and Room Illumination Testing
Document Type:  
Document Number :  Revi sion Number:  4
Page 2of 8CR-6459, v4.0
Page 181 of 200JJVC CONFIDENTIAL
Title:                        Visual Acuity Chart Luminance and Room Illumination Testing
Document Type:  
Document Number :  Revi sion Number:  4
Page 3of 8CR-6459, v4.0
Page 182 of 200JJVC CONFIDENTIAL
Title:                        Visual Acuity Chart Luminance and Room Illumination Testing
Document Type:  
Document Number :  Revi sion Number:  4
Page 4of 8CR-6459, v4.0
Page 183 of 200JJVC CONFIDENTIAL
Title:                        Visual Acuity Chart Luminance and Room Illumination Testing
Document Type:  
Document Number :  Revi sion Number:  4
Page 5of 8CR-6459, v4.0
Page 184 of 200JJVC CONFIDENTIAL
Title:                        Visual Acuity Chart Luminance and Room Illumination Testing
Document Type:  
Document Number :  Revi sion Number:  4
Page 6of 8CR-6459, v4.0
Page 185 of 200JJVC CONFIDENTIAL
Title:                        Visual Acuity Chart Luminance and Room Illumination Testing
Document Type:  
Document Number :  Revi sion Number:  4
Page 7of 8CR-6459, v4.0
Page 186 of 200JJVC CONFIDENTIAL
Title:                        Visual Acuity Chart Luminance and Room Illumination Testing
Document Type:  
Document Number :  Revi sion Number:  4
Page 8of 8CR-6459, v4.0
Page 187 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
APPENDIX E: GUIDELINES FOR COVID -19 RISK MITIGATION  
 
CR-6459, v4.0
Page 188 of 200JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: 5
 
1.0 PURPOSE
The purpose of this doc ument is to provide guidelines for the re -opening or initiation of clinical study sites 
participating in Johnson &Johnson Vision Care, Inc. ( JJVCI )clinical studies dur ing the COVID -19
pandemic.
2.0 SCOPE
This document provides guidelines for Johnson &Johnson Vision Care ( JJVCI )to address the potential risks 
from COVID -19 to study subjects ,investigators, study site staff, and monitors at study sites.The guidance 
provided in this document is in effect from the date of approval through th e date of retirement of this Work 
Instruction. At a minimum ,this Work Instruction will be  reviewed and updated on a quarterly basis, a s
appropriate.
NOTE:  Re-opening of s ites outside of the US will be evaluated on a country by country basis subject 
to local health authority guidance.
3.0 DEFINITIONS
American Academy of Optometry (AAO): The American Academy of Optometry is an organization of 
optometrists based in Orlando, Flor ida. Its goal is to maintain and enhance excellence in optometric 
practice, by both promoting research and the di ssemination of knowledge. The AAO holds an annual 
meeting, publishes a monthly scientific journal, give s credentials to optometrists  through the fellowship 
process and publishes position statements.
American Optometric Association ( AOA ):The American Optom etric Association, founded in 1898, is 
the leading authority on quality care and an advocate for our nation's health, representing more than 44,000 
Doctors of Optometry (O.D.), optometric professionals, and optometry students. Doctor of Optometry take 
a leading role in patient care with respect to eye and vision care, as well as general health and well -being. 
As primary health care providers, Doctor of Optometry have extensive, ongoing training to examine, 
diagnose, treat and manage ocular disorders, diseas es and injuries and sys temic diseases that manifes t in the 
eye. The American Optometric Asso ciation is a federation of state, stud ent, and armed forces optometric 
associations. Through these affiliations, the AOA serves me mbers consisting of optometrists, students of 
optometry, paraoptometric assistants a nd technicians. The AOA and its aff iliates work to provide the public 
with quality vision and eye care.
Center sfor Disease Control and Prevention (CDC ):The Centers for Disease Control and Prevention is a 
national public health institute in the United States. It is a United States federal agency, under the 
Department of Health and Human Services, and is headquartered in Atlanta, Georgia.
COVID -19: Current outbreak of respiratory  disease caused by a novel coronavirus. The virus has been 
named “S ARS -CoV -2” and the disease it causes has been  named “Coronavirus Disease 2019” (COVID -
19).
Clinical Study: Voluntary research studies cond ucted in people and designed to answer specific questions 
about the safety or effectiveness of drugs, vaccines, other therapies, or new ways of using existing 
treatments. May also be called clinical trials, studies, research, trials, or protocols.
Clinical Study Site: Location where a clinical study is  conducted, such as a doctor’s office, university, or 
laboratory. Clin ical studies are conducted by Investigators who are individual(s) responsible for the 
conduct of the clinical study at a study site. If a stud y is conducted by a team of individuals, the 
Investigator is the responsible leader  of the team and may be called the Principal Investigator.
Clinical Operations Manager (COM) :The Johnson & Johnson Vision Care ( JJVC I) individual 
responsible for the overall ma nagement of a clinical trial.
CR-6459, v4.0
Page 189 of 200JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: 5
 
Monitor: Anindividual designated to oversee the progress of a clinical study and ensure that it is 
conducted, recorded, and reported in accordance with  the protocol, Standard Operating Procedures (SOPs), 
Good Clinical Practice (GCP), and ap plicable regulatory requirements.
Medical Safety Officer (MSO) :Physician who has prim ary accountability in their product portfolio for 
product health and safety, and who serves as an independent medical voice for patient safety.
Safety Management Team (SMT) :A cross -functional, collaborative team responsible for review, 
assessment and eva luation of medical safety data arising from any source throughout the product life cycle.
4.0 GUIDANCE FOR STUDY DOCUMENTS
In alignment with recent health authorit yguidance, JJVCI is providing recommendations for study -related 
management in the event of disruption to the conduct of the clinical study. This guidance does not supersede 
any local or government requirements or the clinical judgement of  the investigator to protect the health ,safety
and well -being of particip ants and site staff. If, at an y time, a participant’s safety is considered to be at risk, 
study intervention will be discontinued, and study follow -up will be conducted as outlined in the protocol.  
During the COVID -19 pandemic, the additional risks liste d below need to be considered for study participants 
and study personnel :
Additional Risks Related to the COVID -19 Pandemic:
xThe p ossible transmission of the Coronavi rusinfection and consequent complications, beyond the 
risk of adverse events due to the investigational device and/or procedures .
xThe risk may be higher in an op tometric clinical study because of the close contact the subject will 
have with health care professionals during the proce dures and assessments (since the investigator
must make the measurements close to the subject’s face) and, in addition the need for multiple 
follow -up visits/exams which may expose the subject to other patients and/or healthcare 
professionals who might be transmitting the virus ,even if they do not have symptoms.
xPotential disruptions to the study may be nece ssary due to current or future pandemic -related 
emergency restrictions, which may lead to delays in scheduled follow -up visits.
xSubjects experienc ingan adverse event related to contact lens wear may receive delayed treatment 
due to COVID -19restrictions. In this event, a ll assessments that can be conducted virtually will be 
completed by the investigator to determine the best course of treatment for the subject, including
anunscheduled visit, up to discontinuation from the study , as appropriate .
Ifastudy subject is found to  have contracted COVID -19during participation in astudy, he/she will be 
discontinued from the study and follo wed until COVID -19Adverse Event (AE) resolution.
To help minimize the above potential risks, JJVCI recommend reviewing/complying with local, state, 
and governmental guidance for COVID -19 risks. 
JJVC Iwill provide the following study specific documents wi th language pertaining to COVID -19 risks:
4.1.1 Informed Consent :
Will include information concerning the study -associated risks relate d to the COVID -19 pandemic 
in bold font and/or boxed on the first page of the I nformed Consent document:
CR-6459, v4.0
Page 190 of 200JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: 5
 
STUDY ASSOCIATED RISKS RELATED TO COVID -19 (CORONAVIRUS ) PANDEMIC
It is important to note that this  study will be conducted, at leas t in part, during the COVID -19 pandemic. As such, 
additional risks associated with  the infection with COVID -19 exist for you. Thi s is particularly important for this 
study due, in part, to the closeness of the doctor during the study examinations. 
The potential effects of the dise ase are not fully known, at th is time, and may include long -term serious health 
consequences. In sever e cases, this may result in hospitalization and/or death. Based on current knowledge from the 
Center sfor Disease Control and Prevention (CDC), those at high -risk for severe illness from COVID -19 include 
older adults and people w ith underlying medical cond itions. 
During this study, all appropriate measur es will be taken to minimize risks in cluding the use of personal protective 
equipment such as masks and glov es, as well as proper sanitization. This is in conformance to guidance from the 
CDC, local healt h departments, and the state and county in which the study doctor’s office  is located. However, 
these measures may not completely eliminate th e risks associated with contracting COVID -19. 
If you are found to have contracted COVID -19 or feel ill with flu -like symptoms during pa rticipation in the study, 
you will not be permitted to continue in -office study follow -up visits ,but you will receive instructions and your 
condition will be monitored by the doctor and/or study staff.
4.1.2 COVID -19 Risk Control Check list(Attachment -B):
Will include COVID -19 risk control methods that are required by a site to conduct JJVCI clinical 
studies. The risk controls are consistent with CDC, AOA, AAO Guidance. The Princip al
Investigator will review/sign the study specific  checklist prior to the Site Initiation Meeting.
4.1.3 Protocol Compliance Investigator(s) Signature Page :
Will include a statement indicating thatthePrincipal Investigator ( PI)agrees to conduct the study 
in compliance with all local, state, and governmental guidance’s for COVID -19 risk mitigation. 
I have read the sugges ted guidance provided by JJVCI pertaining to the COVID -19 risk mitigation,
(COVID -19 Work Instruction in the Appendix of this protocol) .I agree to conduct this study in 
compliance with local, state, governmental guidance for COVID -19 risks.
4.1.4 Study Site Initiation Training Slides :
Will include sug gestions to help mitigate potential transmission of COVID -19. Suggestions may 
include maintaining social distan cing in the clinical site by staggered scheduling of study p atients,
wearing proper PPEs, frequ ent disinfection, and installing shields on the s lit lamp and other 
applicable equipment .
5.0 GUIDANCE FOR REMOTE SUBJECT VISITS
Potential disruptions to the study may be nece ssary due to current or future pandemic -related emergency 
restrictions .  Possible disruption of the study as a result of COVID -19 control measures may lead to delays 
in scheduled follow -up visits.
Subjects may be delayed in being seen for study follow up visit(s), for example due to COVID -19 control 
measures or due to the subj ect’s concerns or fears about COVID -19risk.When appropriate , the remote 
assessment willbe conducted to the extent possible.  Discussions with the subject during remote assessments 
may include:
CR-6459, v4.0
Page 191 of 200JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: 5
 
The sponsor will contin ue to monitor the co nduct and progress of the clinical study, and any changes will be 
communicated to the sites and to the health authorities ac cording to local guidance.
 
If a participant has tested positive for COVID -19, the investigator should co ntact the sponsor’s responsible 
medical monitor to discuss initial plan s for study intervention and follow -up. The medical monitor will 
notify the Safety Management Team of a ny subject(s) that have reported “COVID -19”, “ Asymptomatic 
COVID -19”, or “Suspected COVID -19” adverse events within 24 hours of the notification. 
Modifications made to the study c onduct as a result of the COVID -19 pandemic will be summarized in the 
clinical study report.  
COVID -19 screening procedur es that may be mandated by lo cal healthcare systems do not need to be 
reported as an amendment to the protocol even if done during clinical study visits.
Monitoring Visits
When on -site monitoring by the sponsor is not feasible ,the sponsor’s site monitor w ill contact the study 
site to schedule remote visits. In such cases, on -site monitoring visits will resume when feasible, with
increased frequency to address th e source data verification backlog.
Even with staffing lim itations during this COVID -19 pandemic , all routine operations related to clinical 
trials should be well -documented and archived as pa rt of standard process. When conditions permit, all 
parties involved in this clinical  trial should communicate relevant information in a timely  manner so that 
all relevant parties remain  sufficiently informed.
6.1.1 Study Site Initiation:  
During the period that this Work Instruction is in effect , Site Initiation Meetings and training of 
study site staff will be conducted remotely .The JJVCI study team will conduct tr aining via Skype, 
Zoom, Microsoft Teams or similar software as well as utilize online training materials ,as applicable.  
Study site training will be documented utilizing Site Initiation Report
per Study Site Initiation 
On-site visits may be considered when, for example, hands -on training or evaluation of site facilities 
is required. While on site, the Clinical Research Associate ( CRA )will follow all local, state, and 
governmental policies for COVID -19 Risk Mitigation, including socia l distancing, wearing of PPE, 
etc. as applicable for the lo cation of the study site.
6.1.2 Interim Monitoring Visits (if applicable) :
During the period that this Work Instruction is in effect, Interim Monitoring On-site v isits will be 
kept to a minimum and include only those tasks that the CRA cannot perform remotely (e.g., source 
document verification , test article reconciliation, etc.) .
To ensure data integrity during the conduct of all JJVC studies, clinical study teams will follow the 
study specific Clinical Monitoring Plan
While on site, the CRA will follow all local, state,  and governmental policies for COVID -19 Risk 
Mitigation, including social distancing, wearing of PP E, etc. as applicable for the location of the 
study site.
CR-6459, v4.0
Page 193 of 200JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: 5
 
6.1.3 Study Site Closure:  
During the period that this Work Instruction is in effect, the durati on of the Study Site Closure Visit 
willbe lim ited to tasks that the CRA cannot perform re motely (e.g., source document verification, 
test article final rec onciliation and return, etc.).  
CR-6459, v4.0
Page 194 of 200JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: 5
 
Attachment A: Study Site Correspondenc e
XXXX XX, 2020
Re: COVID -19 Mitigation Plan, << CR-xxxx /protocol title>>
Dear <<Princip alInvestigator>> and Study Team,
Coronavirus (COVID -19) has impacted several communities and busi ness activities over the past several months. 
While we work toward the successful  conduct of clinical studies, our commitme nt continues to be the safety of 
patients, healthcare professi onals, and to our communities. 
Therefore, we would like to share th e following revisions/additions related to the above referenced Johnson & 
Johnson Vision Care company sponsored clinical tria l(s) you are currently working on or considering participation 
within. 
Protocol:
xGuidelines for COVID -19 Risk Mitigation provided in the Appendix section.
Protocol Signature Page:
xWill include a statement indicating the Princip al Investigator agrees to conduct the study in compliance 
with all local, state, and gove rnmental guidelines for COVID -19 risk mitigation.
Informed Consent:
xWill include information concerning the study -associated risks related to the COVID -19 pandemic in bold 
font and/or boxed on the first page of the Informed consent document.
COVID -19 Risk Control Checklist for Clinical Studies:
xWill include COVID -19 risk control measures that ar e required to ensure the saf ety and health of subjects, 
site staff and monitors during the pa ndemic.   
We want to encourage the need for open lines of co mmunication about potential challenges you may foresee as the 
result of the current COVID -19 situation. Therefore, we encourage you  to regularly connect with your respective 
Johnson & Johnson cl inical study team ( Clinical Research Associate ( CRA ),Lead CRA or Study Managers).  
Thank you for your continued engageme nt, collaboration, and dedication to your study subjects during this 
challenging time. 
Please file this letter in your s ite file study correspondence. 
CR-6459, v4.0
Page 195 of 200JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: 5
 
RESOURCE LINKS
US Resource Links 
xOSHA Training
https://www.osha.gov/SLTC/covid -19/controlprevention.html
Personal Protective Equipment ( PPE)Training
CDC: https://www.cdc.gov/coronavirus/2019 -ncov/hcp/using -ppe.html
xI&R Training
ACUVUE®LensAssist: https://www.acuvue.com/lensassist    
xClinic Preparedness Guides
CDC: https://www.cdc.gov/coronavirus/2019 -ncov/hcp/clini c-preparedness html
AOA: https://aoa.uberflip.com/i/1240437 -aoa-guidance -for-re-opening -practices -covid·19/1?m4=
American Optom etric Association: https://www.aoa.org/optometry -practice -reactivation -preparedness -
guide
xln-Office Disinfection of Multi -Patient Use Diagnostic Contact Lenses
https://www.gpli.info/wp -content/uploads/2020/03/2020 -01-15-in-office -disinfecting -of-diagnostic -
lenses.pdf
OUS Resource Links 
xUpdates on local regulations in Hong Kong
https://www.coronavirus.gov hk/eng/index.html
xResumption of optical services in England: Letter from Matt Neligan and Poonam Sharma
https://www.england nhs.uk/coronavi rus/wp -content/uploads/sites/52/2020/04/C0601 -reopening -of-optical -
services -letter -17-june-2020.pdf
xNHS Optical Letter
https:/ /www.england nhs.uk/coronavirus/wp -content/uploads/sites/52/2020/04/C0127 -optical -letter -1-april-
2020.pdf
xThe College of Opto metrists primary eye care COVID -19 guidance: Red phase
https://www.college -optometrists.org/the -college/media -hub/news -listing/coronavirus -covid -19-guidance -
for-optometrists .html
xThe College of Optometrists COVID -19: College updates
https://www.college -optometrists.org/t he-college/media -hub/news -listing/coronavirus -2019 -advice -for-
optometrists.html# CollegeGuidelines
xInfection Control Guidelines. (n .d.). Retrieved from Canadian  Association Of Optometrists: 
https://opto.ca/sites/defau lt/files/resources/docume nts/infection_control_guidelines_2016.pdf
xInfection prevention an d control for COVID -19: Interim guidance for outpatient and ambulatory care 
settings. (2020, May 23 May). Retrieved from Govern ment of Canada: https ://www.canada.ca/en/public -
health/services/ diseases/2019 -novel -coronavirus -infection/guidance -documents/interim -guidance -
outpatient -ambulatory -care-settings html
CR-6459, v4.0
Page 198 of 200JJVC CONFIDENTIAL
Title: Guidelines for COVID-19 Risk Mitigation
Document Type:
Document Number: Revision Number: 5
 
xInformation for Members On Coronavirus (COVID -19). (n.d.). Retrieved from Canadian Association Of
Optometrists: 
https://opto.ca/sites/def ault/files/resources/documents/information_for_members_on_coronavirus.pdf
xCoronavirus (COVID -19) resources for health professionals, in cluding aged care providers, pathology 
providers and health care managers. (2020, September 24). Retrieved from Australian Government 
Department of Health:
https://www health.gov.au/res ources/collections/coronavirus -covid -19-resources -for-health -professionals -
including -aged -care-providers -pathology -providers -and-health -care-managers
 
xEnvironmental Cleaning and Disinfection Principles for COVID -19. (n.d.). Retrieved from Australian 
Government Department of Health: 
https://www.health.gov.au/s ites/default/files/documents /2020/03/environmental -cleaning -and-disinfection -
principles -for-covid -19.pdf
xInfection control guidelines and advice. (n .d.). Retrieved from Optometry Australia : 
https://www.optometry.org.au/practice -professional -support/coronavirus -covid -19-what -optometrists -need -
to-know/covid -19-clinical -advice/infection -control -guideline s-and-advice/
 
CR-6459, v4.0
Page 199 of 200JJVC CONFIDENTIAL
Clinical Study Protocol
Johnson & Johnson Vision Care, Inc.
PROTOCOL COMPLIANCE INVESTIGATOR(S) SIGNATURE PAGE  
Protocol Number and Title: CR-6459 Clinical Evaluation of Spherica l Soft Contact Lenses, Toric 
Soft Contact Lenses and Spectacles in Low Astigmats
Version and Date: 4.011 November 2021
I have read and understand the protocol specified above and agree on its content.  
I agree to conduct this study according to ISO 14155 :2020 ,1GCP and ICH guidelines ,2the 
Declaration of Helsinki ,3United States (US) Code of Federal Regulations (CFR) ,4and the 
pertinent individual country laws/regulations and to comply with its obligations, subject to 
ethical and safety considerations. The Principal Investigator is responsib le for ensuring that all 
clinical site personnel, including Sub -Investigators adhere to all ICH2regulations and GCP 
guidelines regarding clinical trials during and after study completion.
I will assure that no deviation from or changes to the protocol will take place without prior 
agreement from the Sponsor and documented a pproval from the Institutional Review Board 
(IRB), except where necessary to eliminate an immediate hazard(s) to the trial participants.
I am responsible for ensuring that all clinical site personnel including Sub -Investigators adhere to 
all ICH2regulations and GCP guidelines regarding clinical trials du ring and after study 
completion.
All clinical site personnel involved in the conduc t of this study have completed Human Subjects 
Protection Training. 
I agree to ensure that all clinical site personnel involved in the conduct of this study are informed 
about their obligations in meeting the above commitments.
I shall not disclose the information contained in  this protocol or any results obtained from this 
study without written authorization.
I have read the suggested guidance provided by JJVCI pertainin g to the COVID -19 risk 
mitigation, (COVID -19 Work Instruction in the Appendix Eof this protocol). I agree to conduct 
this study in compliance with local, state, governmental guidance for COVID -19 risks.
Principal 
Investigator:
Signature Date
Name and Professional Position (Printed)
Institution/Site:
Institution/Site Name
Institution/Site Address
CR-6459, v4.0
Page 200 of 200JJVC CONFIDENTIAL